Sorry, there are no news articles available for .

Latest News By Stage


A

Sorry, there are no articles available for this cancer stage.

More A

Acute Lymphoblastic Leukemia

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

The US Food and Drug Administration has approved Besponsa for the Treatment of Refractory B-cell Precursor Acute Lymphoblastic Leukemia (August 22, 2017)

Besponsa (Inotuzumab ozogamicin) is a targeted therapy designed to bind to B-cell acute lymphoblastic leukemia (ALL) cancer cells that express the CD22 antigen. Acute lymphoblastic leukemia comprises approximately 25% of cancer diagnoses among children... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are... Continue Reading

More Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves IDHIFA A new Targeted Treatment for Acute Myeloid Leukemia (August 10, 2017)

The U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic,... Continue Reading

Precision Therapy Enasidenib Effective in Treating Acute Myeloid Leukemia (June 20, 2017)

According to early clinical trial results published in the journal Blood, some patients with relapsed or treatment-resistant acute myeloid leukemia may achieve remission with an experimental targeted therapy. AML is the most lethal of the blood cancers,... Continue Reading

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis (December 20, 2016)

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly,... Continue Reading

FDA Priority Review Granted for Midostaurin in Leukemia (November 17, 2016)

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis... Continue Reading

More Acute Myeloid Leukemia

Acute Promyelocytic Leukemia

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Acute Promyelocytic Leukemia

Adjuvant (I-III, A-C) Colon Cancer

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (June 27, 2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Advances in Genomic Testing-What you Need to Know (September 29, 2014)

Q: What is genomic testing? A: Genomic testing looks at a group of genes and their varying levels of expression. This gene expression or activity can characterize how genes interact with one another and predict the behavior of certain tissues within... Continue Reading

Oncotype DX Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being (September 22, 2014)

REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer... Continue Reading

More Adjuvant (I-III, A-C) Colon Cancer

Adult Acute Lymphoblastic Leukemia

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (July 18, 2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (October 10, 2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Adult Acute Lymphoblastic Leukemia

Advanced Stage Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of... Continue Reading

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented at the 56th American... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

More Advanced Stage Hodgkin's Lymphoma

Advisory Complementary Alternative Medicine

Combination of Herceptin® with Non–anthracycline-based Chemotherapy Appears to Be Effective (December 15, 2009)

Among women with early, HER2-positive breast cancer, the addition of Herceptin® (trastuzumab) to adjuvant chemotherapy reduces the risk of cancer recurrence and improves survival. Herceptin provides a benefit in combination with either anthracycline-... Continue Reading

More Advisory Complementary Alternative Medicine

Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients (May 28, 2014)

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy... Continue Reading

More Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma

All Cancer Types

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (July 19, 2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Drug Payment Assistance Programs for Cancer (January 25, 2017)

Great advances have been made in the drug treatment of cancer leading to improved cure rates and longer survival. Managing a life threatening or chronic disease, cancer is difficult enough to begin with and can be made much more difficult if you are unable... Continue Reading

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers (December 5, 2016)

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be... Continue Reading

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (July 19, 2016)

Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... Continue Reading

More All Cancer Types

Allogeneic Stem Cell Transplant

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Antiretroviral Drug May Prevent Graft-Versus-Host Disease (August 6, 2012)

The drug Selzentry® (maraviroc), which is typically used to treat HIV infection, may help prevent graft-versus-host disease (GVHD), a potentially lethal complication of stem cell transplants, according to the results of a study published in the New... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

Complementary Therapy for Children Undergoing Stem Cell Transplant (July 19, 2010)

Complementary therapies such as massage and humor therapy may not help children cope with the potential emotional distress associated with stem cell transplantation, according to findings recently reported in Cancer. Stem cell transplantation involves... Continue Reading

Statins May Reduce Acute Graft-versus-host Disease (March 8, 2009)

Statins May Reduce Acute Graft-versus-host Disease Researchers from Ohio State University have reported that statins may reduce the risk of developing acute graft-versus-host disease (GVHD) among patients who undergo allogeneic stem cell transplants.... Continue Reading

More Allogeneic Stem Cell Transplant

Alphabetical Sort

Sorry, there are no articles available for this cancer stage.

More Alphabetical Sort

Alternative Medical Systems Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More Alternative Medical Systems Complementary Alternative Medicine

Anal Cancer

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Anal Cancer Rates Appear to Be On the Rise in the U.S. (May 6, 2013)

The number of people in the United States with anal cancer has tripled since the 1970s, according to the results of a study published in the Journal of Clinical Oncology. Anal cancer is an uncommon type of cancer that occurs in the anal canal, the opening... Continue Reading

More Anal Cancer

Autologous Stem Cell Transplant

Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL (November 12, 2013)

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the... Continue Reading

Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma (March 22, 2013)

Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of... Continue Reading

Complementary Therapy for Children Undergoing Stem Cell Transplant (July 19, 2010)

Complementary therapies such as massage and humor therapy may not help children cope with the potential emotional distress associated with stem cell transplantation, according to findings recently reported in Cancer. Stem cell transplantation involves... Continue Reading

Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)

Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading

Stem Cell Transplant Procedures Vary Throughout the World (March 8, 2009)

Stem Cell Transplant Procedures Vary Throughout the World Stem cell transplant practices vary substantially among physicians treating adults and children with hematologic malignancies (cancers of the blood or bone marrow such as leukemias and lymphomas).... Continue Reading

More Autologous Stem Cell Transplant

B

Sorry, there are no articles available for this cancer stage.

More B

Barrett's Esophagus Esophageal Cancer

Regular Screening of Barrett’s Esophagus Patients Improves Rate of Early Cancer Detection (May 12, 2015)

Patients with Barrett’s esophagus who undergo regular exams have an improved chance that precancerous changes and esophageal cancer will be detected early. These findings were published in the journal Gut. Barrett’s esophagus is a pre-cancerous condition... Continue Reading

Radiofrequency Ablation in Barrett’s Esophagus May Prevent Esophageal Cancer (April 15, 2015)

Treatment of Barrett’s esophagus with radiofrequency ablation appears to keep the condition from progressing to esophageal cancer. These findings were published in the Journal of the American Medical Association. Barrett’s esophagus is a pre-cancerous... Continue Reading

Cytosponge Offers Minimally Invasive Screening Option for Barrett’s Esophagus (March 26, 2015)

Screening for Barrett’s esophagus with a new device called a Cytosponge is accurate compared to endoscopy but less expensive and easier on patients. These findings were reported in the journal PLoS Medicine. Barrett’s esophagus is a pre-cancerous... Continue Reading

Minimally Invasive Endoscopic Procedure Effective in Early Esophageal Cancer (December 4, 2013)

A minimally invasive endoscopic procedure to remove superficial, early stage esophageal is as effective as surgery that removes the entire esophagus, according to the results of a study published in Clinical Gastroenterology and Hepatology. The esophagus... Continue Reading

Surgeon Volume Influences Outcomes in Esophageal Cancer (February 6, 2013)

Patients who undergo surgery for esophageal cancer have a much higher chance of long-term survival if the surgeon has performed the operation many times before, according to the results of a study published in the Journal of Clinical Oncology. The esophagus... Continue Reading

More Barrett's Esophagus Esophageal Cancer

Biologic-Orthomolecular Therapies Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More Biologic-Orthomolecular Therapies Complementary Alternative Medicine

Biological Therapy

Sorry, there are no articles available for this cancer stage.

More Biological Therapy

Bladder Cancer

Avelumab Immunotherapy Approved for Bladder Cancer (May 15, 2017)

Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy... Continue Reading

FDA Approves Imfinzi for Treatment of Urothelial Cancer (May 11, 2017)

The US Food and Drug Administration (FDA) today granted accelerated approval to Imfinzi (durvalumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing... Continue Reading

FDA Approves Opdivo for Treatment of Bladder Cancer (February 16, 2017)

The US Food and Drug Administration (FDA) today approved Opdivo, (nivolumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during a period of up to 1 year after first-line platinum-containing... Continue Reading

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

More Bladder Cancer

Bone Cancer

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

More Bone Cancer

Brain Cancer

Pediatric MATCH Trial to Test Targeted Drugs in Childhood Cancers (August 2, 2017)

Today investigators at the National Cancer Institute (NCI) and the Children’s Oncology Group (COG) announced the opening of enrollment for a unique precision medicine clinical trial. NCI-COG Pediatric Molecular Analysis for Therapy Choice (Pediatric... Continue Reading

Penn Study Suggests that Combining CAR T Cells with Existing Immunotherapies May Overcome Resistance in Glioblastomas (July 24, 2017)

Donald M. O’Rourke, MD Genetically modified “hunter” T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor... Continue Reading

Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few... Continue Reading

More Brain Cancer

Breast Cancer

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer (January 15, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified... Continue Reading

Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer (January 10, 2018)

CancerConnect News: The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

Oral Contraceptive Use Still Linked to Breast Cancer (December 27, 2017)

Women who rely on birth control pills or contraceptive devices that release hormones face a small but significant increase in the risk for breast cancer, according to a large study published in the New England Journal of Medicine.1 This study is the first... Continue Reading

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer (December 14, 2017)

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and... Continue Reading

More Breast Cancer

C

Sorry, there are no articles available for this cancer stage.

More C

Cancer Dictionary

Sorry, there are no articles available for this cancer stage.

More Cancer Dictionary

Carcinoma In Situ Breast cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer (January 20, 2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (September 1, 2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading

More Carcinoma In Situ Breast cancer

Cervical Cancer

Questions to Ask Before Radiation Therapy for the Treatment of Cervical Cancer (December 13, 2017)

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. Doctors who specialize in treating cancers with radiation are known as radiation oncologists. During radiation therapy, high-energy x-rays are used to kill cancer cells. Radiation... Continue Reading

Managment of the Side Effects of Radiation for Cervical Cancer (December 7, 2017)

Radiation therapy, or radiotherapy, is a common way to treat cervical cancer. With any treatment of cancer you must first understand your responsibility and your medical team’s role as well as explore treatment options and get a second opinion(s) before... Continue Reading

What You Should Know About the Side Effects of Surgery for Cervical Cancer (December 6, 2017)

A hysterectomy is a common surgical treatment of early stage cancer and precancerous disease of the cervix in women. With any treatment of cancer it is important to first understand your responsibility and your medical team’s role as well as explore... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment (August 17, 2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average... Continue Reading

Genmab Announces Preliminary Cervical Cancer Data from Tisotumab Vedotin Phase I/II Study (July 5, 2017)

Data from an ongoing clinical study of tisotumab vedotin in solid tumors has demonstrated activity in the treatment of cervical cancer; 11 of 34 evaluable patients achieved a response; with a median time of treatment of 4.9 months and 7 responders are... Continue Reading

More Cervical Cancer

Chemotherapy

Head and Neck Cancer Patients at Risk of Cognitive Problems Following Treatment (January 8, 2018)

CancerConnect News: Patients who survive head and neck cancer may be more likely to experience declines in mental function according to the results of a recent study. The findings are drawn from cognitive assessments for 80 survivors of head and neck... Continue Reading

Cervical Cancer Survivors Frequently Suffer From Long-Term Side Effects of Treatment (August 17, 2017)

According to a new study around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue or hot flushes.1 Cervical cancer affects more than 500,000 women around the world each year with an average... Continue Reading

Balance and Gait is Negatively Impacted By Chemotherapy Treatment (July 26, 2017)

A single chemotherapy treatment can result in a significant negative impact on walking gait and balance, putting patients at an increasing risk for falls, according to a new study involving breast cancer patients conducted by researchers at The Ohio State... Continue Reading

Shorter Duration Chemotherapy Possible for Early Stage Colon Cancer (June 26, 2017)

Many colon cancer patients can cut their chemotherapy regimen in half, improving their quality of life and reducing their chances of having debilitating side effects, according to the results of a major study released at the American Society of Clinical... Continue Reading

Syndros™ Approved for Treating Chemotherapy-Induced Nausea and Vomiting (July 12, 2016)

The orally administered liquid formulation, Syndros (dronabinol), has been approved by the United States Food and Drug Administration (FDA) for the treatment of chemotherapy-induced nausea and vomiting. Syndros is an oral formulation comparable to the... Continue Reading

More Chemotherapy

Childhood Acute Lymphoblastic Leukemia

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia (September 26, 2016)

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab)... Continue Reading

One Subset of Childhood Acute Lymphoblastic Leukemia is Best Treated with Chemotherapy (April 20, 2012)

A subset of young patients with acute lymphoblastic leukemia (ALL) who fail to achieve remission after the initial weeks of intense chemotherapy known as induction therapy appear to have better outcomes with additional chemotherapy rather than bone marrow... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Childhood Acute Lymphoblastic Leukemia

Chronic Lymphoblastic Leukemia

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (July 11, 2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (February 29, 2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not... Continue Reading

FDA Approves New Treatment Options for Low Grade Lymphomas and Chronic Lymphocytic Leukemia (August 25, 2014)

Gilead Sciences has confirmed FDA approval of Zydelig (idelalisib) for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL). Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the cells... Continue Reading

Gazyva/Chlorambucil Improves Outcomes in Older CLL Patients with Other Health Problems (December 16, 2013)

Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was more effective than treatment with Rituxan® (rituximab) and chlorambucil. These results were presented... Continue Reading

More Chronic Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (September 11, 2017)

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced... Continue Reading

Personalized Cell Therapy Combined with Imbruvica Achieves Complete Remission in High Percentage of Chronic Lymphocytic Leukemia Patients (June 5, 2017)

Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (July 11, 2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia (March 23, 2016)

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

More Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Sprycel Effective for Treatment of Pediatric Chronic Myeloid Leukemia (June 14, 2017)

In 2002, the FDA approved the drug Gleevec (imatinib) as a first-line therapy for adults with chronic myeloid leukemia (CML) caused by the fusion gene BCR-ABL, known as the Philadelphia chromosome. The approval dramatically extended the lives of patients... Continue Reading

Have a Question about Chronic Myeloid Leukemia? Join us on May 25th! (May 2, 2017)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Luskin CancerConnect announces the opportunity to engage with leukemia expert, Marlise Luskin, MD, MSCE. On May 25th, 2017, Dr. Luskin will answer your pre-submitted questions... Continue Reading

FDA Grants Iclusig® Expanded Approval for CML (December 14, 2016)

The United States Food and Drug Administration (FDA) has granted Iclusig® (ponatinib) approval to treat all phases of chronic myeloid leukemia (CML) in adults, as well as Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are... Continue Reading

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia (April 7, 2015)

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented... Continue Reading

More Chronic Myeloid Leukemia

Clinical Trials Database

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (July 18, 2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology... Continue Reading

More Clinical Trials Database

Colon Cancer

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (October 16, 2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading

NSAIDs Decrease Risk of Colorectal Cancer (September 18, 2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively... Continue Reading

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know (July 17, 2017)

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular... Continue Reading

More Colon Cancer

Complementary Alternative Medicine

Acupuncture Reduces Aromatase Inhibitor Joint Pain in Women with Breast Cancer (December 14, 2017)

According to a well designed study presented at the 2017 San Antonio Breast Cancer Symposium acupuncture is effective in reducing pain and stiffness associated with aromatase inhibitor (AI) therapy in women with early-stage breast cancer.1 Stiffness and... Continue Reading

Alternative Medicine Used Alone Appears to Reduce Survival Rates in Cancer Patients (August 16, 2017)

Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research Center... Continue Reading

High Prevalence of CAM Use Among Thyroid Cancer Patients (November 1, 2010)

Among patients with thyroid cancer, use of complementary and alternative medicine is common, with more than 80% reporting use. These results were presented at the 14th International Thyroid Congress. Complementary and alternative medicines are therapies... Continue Reading

Fish Oil Linked to Reduction in Breast Cancer Risk (July 9, 2010)

A recent study suggests that regular use of fish oil supplements may reduce the risk of breast cancer. These findings were published in the journal of Cancer Epidemiology, Biomarkers & Prevention.[1] Dietary supplements are a booming business—Americans... Continue Reading

Use of Complementary and Alternative Medicine Common in Pediatric Cancer Patients (April 9, 2010)

Pediatric cancer patients commonly use complementary and alternative medicine (CAM), according to a review article recently published in the journal Pediatrics.[1] The landscape of medicine has been dramatically changing over the past several decades.... Continue Reading

More Complementary Alternative Medicine

Corticosteroid

Sorry, there are no articles available for this cancer stage.

More Corticosteroid

D

Sorry, there are no articles available for this cancer stage.

More D

Drug Dictionary

Sorry, there are no articles available for this cancer stage.

More Drug Dictionary

E

Sorry, there are no articles available for this cancer stage.

More E

Early Stage Hodgkin's Lymphoma

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care (December 12, 2014)

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented at the 56th American... Continue Reading

Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin’s Lymphoma (October 30, 2014)

According to a large observational study based on the National Cancer Database (NCDB), adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage I and II Hodgkin’s lymphoma (HL).  The findings... Continue Reading

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma (February 26, 2014)

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed,... Continue Reading

Children with Favorable-Risk Hodgkin’s Lymphoma May Benefit from Limited Radiation Therapy (July 6, 2012)

Children with favorable-risk Hodgkin’s lymphoma who achieve a complete early response to chemotherapy may not require radiation therapy or may undergo limited radiation therapy, according to the results of a study published in the Journal of the American... Continue Reading

Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)

Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading

More Early Stage Hodgkin's Lymphoma

Early Stage I-II (A-B) Prostate Cancer

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (April 25, 2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (November 5, 2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer.... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

More Early Stage I-II (A-B) Prostate Cancer

Esophageal Cancer

Diagnosed with Esophageal Cancer: 10 Tips on How to Get The Most From Your Doctor (December 1, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with esophageal cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

New Standard of Care for Treatment of Resectable Gastric Cancer (October 3, 2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable... Continue Reading

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (September 25, 2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors,... Continue Reading

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer? (December 8, 2016)

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP),... Continue Reading

More Esophageal Cancer

Ewing's Sarcoma Overview

Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)

In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading

Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading

Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading

More Ewing's Sarcoma Overview

Extensive Lung Cancer - Small Cell

Keytruda® Active in Small Cell Lung Cancer (December 27, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (February 11, 2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported... Continue Reading

Advanced Squamous Cell Lung Cancer: The Lung-MAP Trial (January 13, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Innovative Clinical Trials for Lung Cancer Currently Underway (January 7, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Chest Radiation Improves Survival in Extended-Stage Small Cell Lung Cancer (November 4, 2014)

The results of a recently reported clinical study at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco demonstrate that thoracic radiation improves survival and reduces cancer recurrence when added to prophylactic... Continue Reading

More Extensive Lung Cancer - Small Cell

F

Sorry, there are no articles available for this cancer stage.

More F

Follicular Lymphoma

FDA Approves Aliqopa for Treatment of Adults with Relapsed Follicular Lymphoma (October 18, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients... Continue Reading

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (January 5, 2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be... Continue Reading

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (December 15, 2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

More Follicular Lymphoma

G

Sorry, there are no articles available for this cancer stage.

More G

Gastric Cancer

Diagnosed with Gastric Cancer: 10 Tips on How to Get The Most From Your Doctor (December 21, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with gastric cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including nurses... Continue Reading

New Standard of Care for Treatment of Resectable Gastric Cancer (October 3, 2017)

The superiority of docetaxel based triplet therapy over standard care in patients with resectable esophago-gastric cancer has been confirmed in late-breaking results from the FLOT4 trial presented at the ESMO 2017 Congress in Madrid.1 Survival in resectable... Continue Reading

The US Food and Drug Administration has Expanded the Approval of the Precision Cancer Medicine Keytruda for Treatment of Gastric Cancer (September 25, 2017)

Keytruda (Pembrolizumab) is now indicated for patients with recurrent locally advanced or metastatic gastric or gastro-esophogeal junction adenocarcinoma. Patients eligible for keytruda therapy under this new indication must have PD-L1-expressing tumors,... Continue Reading

Keytruda Immunotherapy Appears Promising in Advanced Gastric Cancer (September 18, 2017)

Keytruda (pembrolizumab) appears promising in patients with pretreated metastatic gastric cancer, according to late-breaking results from the KEYNOTE-059 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.1 Stomach... Continue Reading

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer (February 6, 2017)

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer... Continue Reading

More Gastric Cancer

Gastrointestinal Stromal Tumors

SWOG Study Shows Strong Long-Term Survival Rates for Patients with GIST (April 26, 2017)

PORTLAND, OR – Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed as Gleevec.... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

More Gastrointestinal Stromal Tumors

Gene Therapy

New Substances Added to List of Cancer-Causing Agents (June 21, 2011)

In the most recent version of the National Toxicology Program’s Report on Carcinogens, two new substances have been classified as “known human carcinogens” and six others have been classified as “reasonably anticipated to be human carcinogens.” The... Continue Reading

More Gene Therapy

General

Cancer Patients are Relatively Unaware of the Role of Precision Cancer Medicine, Genomics and Biomarker Testing (January 8, 2018)

CancerConnect News: Precision cancer medicines and the companion tests used to identify them are increasingly important in the management of cancer.  It is important to understand how aware patients are of these evolving treatment options and whether... Continue Reading

What to Tell Children when Facing a Diagnosis of Cancer (December 14, 2017)

If you have children in your life, you already know that they tend to be creatures of habit who rely on their daily routine. There may be unexpected changes in their routine with your fight against cancer, and you may be concerned about the best way to... Continue Reading

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available (December 7, 2017)

The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare &... Continue Reading

Understanding Low Back Pain (December 1, 2017)

From theSpineCommunity Back pain is a symptom associated with over 60 different medical conditions.  These disorders involve a number of different organ systems.  A variety of healthcare professionals have expertise that can be useful in the diagnosis... Continue Reading

Flu Shot 101 – What You Need to Know (October 19, 2017)

Flu season is here again, and besides a fever and runny nose, it can bring about the longtime controversy surrounding vaccines. In order to protect more human lives this year and to clarify some of the most common misconceptions surrounding the flu vaccine,... Continue Reading

More General

General Bone Cancer

Xgeva Safe and Effective for Giant Cell Tumor of the Bone (August 6, 2013)

The planned interim results of an international, open-label, phase 2 clinical trial published in the Lancet Oncology indicate that Xgeva® (denosumab) is safe and effective in the treatment of giant cell tumor of the bone. In fact, 96 percent of patients... Continue Reading

Xgeva Approved for Treatment of Giant Cell Tumor of the Bone (July 17, 2013)

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB). Giant cell tumor of bone (GCTB) is a rare, aggressive, benign... Continue Reading

Xgeva Reduces Giant-cell Tumor of the Bone (October 2, 2012)

Xgeva® (denosumab) significantly reduced or eliminated tumor giant cells in patients with giant-cell tumor of the bone and also increased new bone formation, according to the results of a phase II study published in Clinical Cancer Research. Giant cell... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Xgeva Delays Onset of Bone Metastases (September 27, 2011)

Among men with prostate cancer that has stopped responding to hormonal therapy, the bone drug Xgeva™ (denosumab) delayed the spread of cancer to the bones. These results were presented at the 2011 European Multidisciplinary Cancer Conference. Androgen... Continue Reading

More General Bone Cancer

General Brain Cancer

Addition of Temodar® to Radiation in Glioma: New Standard of Care (January 19, 2017)

The addition of the chemotherapy agent, Temodar® (temozolomide), to radiation therapy has demonstrated a huge survival benefit compared to treatment with radiation therapy alone among patients with newly diagnosed glioma. These results were recently... Continue Reading

Temodar® After Radiation Improves Survival in Anaplastic Gliomas (June 7, 2016)

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results... Continue Reading

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma (May 23, 2016)

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few... Continue Reading

Optune Approved for Newly Diagnosed Glioblastoma Multiforme (October 22, 2015)

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is an extremely aggressive form of brain cancer. Average... Continue Reading

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment (July 13, 2015)

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented at 2015 Annual Meeting of the American Society... Continue Reading

More General Brain Cancer

General Complementary Alternative Medicine

Sorry, there are no articles available for this cancer stage.

More General Complementary Alternative Medicine

General Gene Therapy

Sorry, there are no articles available for this cancer stage.

More General Gene Therapy

General Head and Neck Cancer

Twice-daily radiation therapy reduces mortality from head and neck cancer (February 14, 2017)

Treating head and neck cancer patients with a twice-daily radiation therapy schedule combined with chemotherapy could save more lives, according to new research presented at the European Cancer Congress 2017.1 Around 600,000 people are diagnosed with... Continue Reading

Opdivo Approved for Advanced Head and Neck Cancer (November 28, 2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the... Continue Reading

PET/CT Combined More Effective Than MRI in Monitoring Head and Neck Cancer Patients’ Response to Treatment (October 5, 2016)

According to a recent study, combining PET/CT to monitor response to treatment in head and neck cancer patients appears more effective than MRI. Using PET/CT may better inform doctors whether treatment for head and neck cancer is working after just one... Continue Reading

Keytruda® Approved for Advanced Head and Neck Cancer (September 7, 2016)

The United States Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) for the treatment of advanced head and neck cancer that has stopped responding to platinum-based chemotherapy agents.1 Globally, head and neck cancer comprises... Continue Reading

Compliance with Radiation Schedules Improves Survival in Head and Neck Cancer (June 9, 2016)

Patients with head and neck cancer who comply with their scheduled radiation treatments have significantly improved outcomes compared to those who miss 2 or more of their appointments within the prescribed time period. These results were recently published... Continue Reading

More General Head and Neck Cancer

General HIV Related Cancers

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Cancer Burden Has Changed for People with HIV/AIDS (April 14, 2011)

Among people living with AIDS in the United States, the frequency of AIDS-defining cancers such as Kaposi sarcoma decreased markedly between 1991 and 2005; the frequency of other types of cancer, however, increased three-fold. These results were published... Continue Reading

Study Evaluates Impact of Highly Active Antiretroviral Therapy (HAART) on Cancer Risk in HIV-infected Men (August 10, 2010)

Researchers reported that men infected with human immunodeficiency virus (HIV) are still at an increased risk of lymphoma, Kaposi’s sarcoma (KS), and anal cancer despite the introduction of highly active antiretroviral therapy (HAART). These findings... Continue Reading

More General HIV Related Cancers

General Lung Cancer

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Keytruda® Active in Small Cell Lung Cancer (December 27, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading

Personalized Lung Cancer Care & Precision Medicine (November 8, 2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

More General Lung Cancer

General Malignant Mesothelioma

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

MVP Does Not Provide Benefit in Mesothelioma Patients (May 21, 2008)

MVP Does Not Provide Benefit in Mesothelioma Patients The chemotherapy agent Navelbine® (vinorelbine) may improve outcomes for patients with malignant pleural mesothelioma. However, the combination chemotherapy regimen referred to as MVP (mitoxantrone,... Continue Reading

Minimally Invasive Endoscopic Procedure Shows Promise for Detecting Lung Cancer (February 8, 2008)

Minimally Invasive Endoscopic Procedure Shows Promise for Detecting Lung Cancer Use of a minimally invasive technique called endoscopy to detect lung cancer may be more effective than more complicated and invasive standard procedures. These findings were... Continue Reading

More General Malignant Mesothelioma

General Myelodysplastic Syndrome

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (August 31, 2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents.... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

More General Myelodysplastic Syndrome

General Neuroblastoma

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Improved Survival with Busulphan-Melphalan Chemotherapy in Pediatric Neuroblastoma (June 8, 2011)

Treatment with high doses of the chemotherapy combination including busulphan and melphalan significantly improves survival and reduces cancer progression among pediatric patients with high-risk neuroblastoma. These results were presented at a plenary... Continue Reading

Reduced Chemotherapy Regimen May Be Effective in Neuroblastoma (November 10, 2010)

According to results of a Phase III clinical trial, patients with intermediate-risk neuroblastoma may be effectively treated with reduced doses of chemotherapy given over a shorter period. These findings were published in the New England Journal of Medicine. Neuroblastoma... Continue Reading

More General Neuroblastoma

General Renal Cancer

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical... Continue Reading

Lenvima® Approved for Kidney Cancer (May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading

Cabometyx® Approved for Kidney Cancer (May 10, 2016)

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already... Continue Reading

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide (March 15, 2016)

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and... Continue Reading

FDA Approves Opdivo for Renal Cell Carcinoma (November 25, 2015)

The FDA granted approval to nivolumab (Opdivo) for patients with renal cell carcinoma. Opdivo, a PD-1 inhibitor, was previously approved for the treatment of melanoma whose tumors express the BRAF V600 mutation as well as advanced non-small cell lung... Continue Reading

More General Renal Cancer

General Retinoblastoma

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Retinoblastoma Survivors Face Risk of Second Cancers (March 8, 2009)

Retinoblastoma Survivors Face Risk of Second Cancers A study that followed retinoblastoma survivors for up to 61 years reported a high risk of second cancers among survivors of hereditary retinoblastoma. These results were published in the Journal of... Continue Reading

Chemotherapy for Retinoblastoma Delivered Directly into Eye May Save Eye (March 8, 2009)

Chemotherapy for Retinoblastoma Delivered Directly into Eye May Save Eye Chemotherapy delivered directly into the artery of the eye may save the eyeball in children with retinoblastoma. These results were recently published in an early online publication... Continue Reading

More General Retinoblastoma

General Sarcoma

YONDELIS® (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma (February 4, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for YONDELIS® (trabectedin) to treat patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes. YONDELIS®... Continue Reading

Carbon Ion Beam Radiation Effective in Spinal Sarcomas (September 6, 2013)

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of cancers arising from fibrous tissue, adipose tissue... Continue Reading

Regorafenib May Expand GIST Treatment Options (June 13, 2012)

Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading

Votrient Approved for the Treatment of Sarcoma (May 7, 2012)

The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft... Continue Reading

Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST) (April 9, 2012)

In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results... Continue Reading

More General Sarcoma

General Skin Cancer

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Promising Activity of Pembrolizumab in Merkel Cell Carcinoma (June 14, 2016)

Treatment of 26 patients with advanced previously untreated Merkel cell carcinoma with Keytruda® (pembrolizumab) every three weeks resulted in an overall response rate of 56% suggesting this novel therapy could represent a new treatment option for these... Continue Reading

National "Check Yourself to Protect Yourself ALL YEAR" Campaign Highlights Need for Year-Round Skin Cancer Prevention (November 12, 2015)

Although one in five Americans will get skin cancer in their lifetimes, 65 percent of people of color don’t believe they are at risk and face lower survival rates as a result. To change these odds, the cancer organization Patients Rising will use... Continue Reading

Patients with Multiple Squamous Cell Carcinomas Should be Frequently Monitored (October 21, 2015)

Patients with multiple sites of cutaneous squamous cell carcinoma (a type of skin cancer) have a significantly increased risk of developing a recurrence or spread to their lymph nodes, warranting frequent follow-up visits to their dermatologist. These... Continue Reading

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma (August 13, 2015)

The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates... Continue Reading

More General Skin Cancer

General Thyroid Cancer

Pass it On: It’s National Thyroid Awareness Month (September 8, 2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer happens when cells in the thyroid grow out of control.... Continue Reading

Nexavar Approved for Metastatic Differentiated Thyroid Cancer (December 9, 2013)

The U.S. Food and Drug Administration (FDA) has approved Nexavar® (sorafenib) for the treatment of metastatic differentiated thyroid cancer. Differentiated thyroid cancer is the most common type of thyroid cancer and can often be cured with surgery and... Continue Reading

Mutations Linked to Drug Response in Medullary Thyroid Cancer (November 15, 2013)

Metastatic medullary thyroid cancers with certain genetic mutations respond better to treatment with Cometriq™ (cabozantinib) than tumors without those mutations, according to the results of a study presented at the 83rd Annual Meeting of the American... Continue Reading

TSH Suppression after Thyroidectomy May Not Be Beneficial (November 4, 2013)

Suppression of thyroid-stimulating hormone (TSH) after thyroidectomy for low-risk cancer does not appear to reduce the risk of cancer recurrence and may even increase the risk of osteoporosis in women, according to the results of a study presented at... Continue Reading

Thyroid Ultrasound May Cut Biopsy Rate (September 13, 2013)

Thyroid ultrasound may help identify certain characteristics of thyroid nodules that can predict the likelihood of cancer—and subsequently help determine whether biopsy is necessary, according to the results of a study published in the Journal of the... Continue Reading

More General Thyroid Cancer

General Vaginal Cancer

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

DES Daughters Have Increased Risk of Cancer (October 18, 2011)

According to a study published in the New England Journal of Medicine, women exposed to diethylstilbestrol (DES) before birth have an increased risk of vaginal cancer, cervical precancers, and breast cancer. These women also have an increased risk for... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Tumor Burden in Sentinel Node May Help Stratify High- and Low-risk Vulvar Cancer Patients (June 15, 2010)

Tumor burden in the sentinel node of early-stage vulvar cancer patients appears to be an important prognostic factor. Patients with sentinel-node metastasis larger than 2mm may have a worse prognosis. These findings were recently published in the journal... Continue Reading

More General Vaginal Cancer

H

Sorry, there are no articles available for this cancer stage.

More H

Hairy Cell Leukemia

Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment (October 7, 2015)

The medication Zelboraf® (vemurafenib) appears active in the treatment of hairy cell leukemia (HCL) that had progressed after previous therapy. These findings were published in New England Journal of Medicine. Hairy cell leukemia is a rare type of leukemia,... Continue Reading

Zelboraf® Active in Hairy Cell Leukemia (September 24, 2015)

The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Hairy Cell Leukemia

Head and Neck Cancer

Head and Neck Cancer Patients at Risk of Cognitive Problems Following Treatment (January 8, 2018)

CancerConnect News: Patients who survive head and neck cancer may be more likely to experience declines in mental function according to the results of a recent study. The findings are drawn from cognitive assessments for 80 survivors of head and neck... Continue Reading

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial (August 21, 2017)

CEL-SCI Corporation today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has... Continue Reading

Head and Neck Cancer-What You Need to Know (August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading

Targeted radiotherapy for head and neck cancer could reduce the risk of dry mouth (February 22, 2017)

A troublesome side effect of radiation therapy treatment of cancers involving the head and neck is dry mouth.  This occurs as a consequence of radiation damage to the salivary glands.  According to a new study, changing the intensity of radiotherapy... Continue Reading

Nearly half of U.S. men actively infected with HPV, study finds HPV-linked cancers on the rise in men, but nearly 9 in 10 vaccine-eligible men are unvaccinated! (February 20, 2017)

By Rachel Tompa / Fred Hutch News Service The most common sexually transmitted infection in the U.S. has a bit of a twist. It’s what’s known as a “subclinical infection” — those infected suffer no immediate consequences, but years later have... Continue Reading

More Head and Neck Cancer

Health and Wellness

Understanding Low Back Pain (December 1, 2017)

From theSpineCommunity Back pain is a symptom associated with over 60 different medical conditions.  These disorders involve a number of different organ systems.  A variety of healthcare professionals have expertise that can be useful in the diagnosis... Continue Reading

Skin Cancer Prevention Tips from the Skin Cancer Foundation (May 17, 2017)

The development of skin cancer is certainly a risk for any individual, but particularly for those of us who spend time in the outdoors. As summer approaches it’s important to keep in mind that by taking certain steps to protect yourself from the sun,... Continue Reading

CDC Vaccine Information and Recommendations for the 2016/17 Influenza Season (September 22, 2016)

With the start of a new school year and the approaching winter, it’s time to get informed about the most critical information regarding the 2016/17 influenza vaccines and CDC’s vaccination recommendations. The CDC recommends that everyone aged 6... Continue Reading

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

More Health and Wellness

Hepatocellular Carcinoma Liver Cancer

Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer (November 26, 2012)

Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (July 10, 2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading

Women with Hypothyroidism at Increased Risk of Liver Cancer (June 22, 2009)

Women with Hypothyroidism at Increased Risk of Liver Cancer Long-term hypothyroidism in women significantly increases the risk of developing hepatocellular carcinoma (liver cancer), according to the results of a study published in Hepatology.[1] The liver... Continue Reading

Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF (March 8, 2009)

Increased Risk of Liver Cancer for Patients with Cirrhosis Who Overexpress EGF According to an article recently published in the Journal of the American Medical Association, patients with cirrhosis of the liver who overexpress epithelial growth factor... Continue Reading

Nexavar® Added to Treatment Guidelines for Liver Cancer (March 8, 2009)

Nexavar® Added to Treatment Guidelines for Liver Cancer The drug Nexavar® (sorafenib) has been added to the list of treatment options for patients with liver cancer who are not eligible for a liver transplant. This was reported in a recent presentation... Continue Reading

More Hepatocellular Carcinoma Liver Cancer

Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading

Treatment with Early Stem Cell Transplant Improves Outcomes in Aggressive NHL (November 12, 2013)

Early autologous stem cell transplantation resulted in improved progression-free survival in patients with high-intermediate risk or high-risk disease who experienced a response to induction therapy, according to the results of a study published in the... Continue Reading

More Highly Aggressive/High Grade Non-Hodgkin's Lymphoma

HIV Related Cancers

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

More HIV Related Cancers

Hodgkin's Lymphoma

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (December 1, 2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (April 28, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer... Continue Reading

More Hodgkin's Lymphoma

Hormonal Therapy

Sorry, there are no articles available for this cancer stage.

More Hormonal Therapy

I

Sorry, there are no articles available for this cancer stage.

More I

Indolent/Low Grade Non-Hodgkin's Lymphoma

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia (February 24, 2015)

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 8, 2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading

More Indolent/Low Grade Non-Hodgkin's Lymphoma

Inflammatory Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Walk or Run Your Way to a Reduced Risk of Breast Cancer (September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading

More Inflammatory Breast Cancer

Info Type

Kyprolis Improves Progression-Free Survival in Multiple Myeloma (August 7, 2014)

Amgen announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE met its primary endpoint of progression-free survival (PFS).  Patients treated with Kyprolis® (carfilzomib) in combination with Revlimid® (lenalidomide)... Continue Reading

(August 6, 2014)

The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are... Continue Reading

Gazyva Approved for CLL (November 22, 2013)

The U.S. Food and Drug Administration (FDA) has approved Gazyva™ (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Chronic lymphocytic leukemia (CLL) is the most common... Continue Reading

More Info Type

J

Sorry, there are no articles available for this cancer stage.

More J

K

Sorry, there are no articles available for this cancer stage.

More K

L

Sorry, there are no articles available for this cancer stage.

More L

Leukemia

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (September 19, 2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates... Continue Reading

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia (September 5, 2017)

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

FDA Approves First Gene Therapy (September 1, 2017)

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering... Continue Reading

More Leukemia

Limited Disease Lung Cancer - Small Cell

Innovative Clinical Trials for Lung Cancer Currently Underway (January 12, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Innovative Clinical Trials for Lung Cancer Currently Underway (January 7, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Prophylactic Cranial Irradiation May Improve Survival in Small Cell Lung Cancer (June 14, 2011)

Radiation to the brain prior to detectable spread of cancer to the brain improved survival in patients with both early- and late-stage small cell lung cancer. These results were recently presented at the 2011 meeting of the American Society of Clinical... Continue Reading

Most Survivors of Lung and Colorectal Cancer Keep Their Jobs (April 15, 2010)

Among people diagnosed with nonmetastatic lung or colorectal cancer, the majority return to work, according to a study recently published in Journal of Clinical Oncology. Those who do leave the workforce tend to have worse prognoses and lower socioeconomic... Continue Reading

Smoking Cessation After Lung Cancer Diagnosis Improves Survival (February 11, 2010)

Quitting smoking after a diagnosis of early-stage lung cancer may reduce the risk of cancer recurrence and death. These results were published in the British Medical Journal. Lung cancer is the leading cause of cancer death in the United States, with... Continue Reading

More Limited Disease Lung Cancer - Small Cell

Liver Cancer

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer (May 18, 2017)

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with... Continue Reading

First New Drug for Liver Cancer in a Decade: Stivarga (May 8, 2017)

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s... Continue Reading

February: Gallbladder and Bile Duct Awareness Month (February 18, 2016)

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (February 11, 2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Infection with Hepatitis C Increases Risk of Cirrhosis (March 10, 2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

More Liver Cancer

Locally Advanced Stage III (C) Prostate Cancer

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (August 17, 2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Radiation Plus Androgen-Deprivation Therapy Prolongs Survival for Older Men With Prostate Cancer (January 20, 2015)

According to the results of a study recently published in the Journal of Clinical Oncology, the addition of radiation treatment to treatment with androgen-deprivation therapy (ADT) in older men with locally advanced prostate therapy prolongs survival... Continue Reading

Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations (December 10, 2014)

CancerConnect News: Genomic Health, Inc. today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment... Continue Reading

More Locally Advanced Stage III (C) Prostate Cancer

Lung Cancer

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients (January 15, 2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

More Lung Cancer

Lung Cancer - Non-Small Cell

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

First Line Combination Therapy Improves Progression-Free Survival In Advanced Lung Cancer (January 8, 2018)

A recently reported study confirms that combination therapy using the “checkpoint inhibitor” Tecentriq® (atezolizumab) and chemotherapy as first line treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free... Continue Reading

The Role of Immunotherapy in the Treatment of Advanced Non Small Cell Lung Cancer (December 6, 2017)

Treatment options for advanced NSCLC fit into 3 main categories… Targeted Therapy – we test lung cancer for specific mutations to see if we have an appropriate targeted medication. Immunotherapy – if targeted therapy is not an option immunotherapy... Continue Reading

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer (November 13, 2017)

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December... Continue Reading

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain (September 21, 2017)

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC)... Continue Reading

More Lung Cancer - Non-Small Cell

Lung Cancer - Small Cell

Keytruda® Active in Small Cell Lung Cancer (December 27, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause... Continue Reading

Personalized Lung Cancer Care & Precision Medicine (November 8, 2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by... Continue Reading

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows (June 6, 2016)

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options.... Continue Reading

NFCR-Support Research Finds New Way to Combat Resistant Lung Cancer (February 11, 2015)

A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported... Continue Reading

Advanced Squamous Cell Lung Cancer: The Lung-MAP Trial (January 13, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

More Lung Cancer - Small Cell

Lymphoma

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL (July 12, 2017)

Recommendation based on review of CTL019 r/r B-cell ALL development program, including the pivotal Phase II global ELIANA trial  A Biologics License Application (BLA) for this indication is under FDA priority review; if approved, CTL019 could become... Continue Reading

Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma (May 4, 2017)

Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently at the American Society of Hematology Annual Meeting in San Diego, California.  Overall 76%... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

More Lymphoma

M

Sorry, there are no articles available for this cancer stage.

More M

Management and Prevention of Anemia Supportive Care

Exercise Reduces Chemotherapy-related Fatigue (October 21, 2009)

Exercise reduces fatigue and improves strength, physical functioning, and emotional well-being in men and women undergoing chemotherapy, according to the results of a study published in the British Medical Journal.[1] While exercise has long been associated... Continue Reading

More Management and Prevention of Anemia Supportive Care

Management and Prevention of Anorexia and Weight Loss Supportive Care

Fish Oil May Help Patients Maintain Weight During Chemotherapy (March 8, 2011)

Fish oil, taken as a dietary supplement, may help prevent muscle and weight loss among cancer patients who are undergoing chemotherapy. These findings were reported in the journal Cancer. Loss of muscle and weight is a potential side effect of chemotherapy... Continue Reading

More Management and Prevention of Anorexia and Weight Loss Supportive Care

Management and Prevention of Bone Complications Supportive Care

Xgeva Reduces Bone Complications From Prostate Cancer (February 25, 2011)

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial were published in The... Continue Reading

Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer (December 21, 2010)

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III clinical trial were presented at the 2010 San Antonio... Continue Reading

Denosumab Delays Bone Complications in Women with Metastatic Breast Cancer (November 23, 2010)

Among women with bone metastases from breast cancer, denosumab may be more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase III clinical trial were published in the Journal... Continue Reading

Denosumab More Effective Than Zometa at Delaying Bone Complications (October 15, 2010)

Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading

Bisphosphonates May Provide Breast Cancer Benefits (December 11, 2009)

Studies presented at the 2009 San Antonio Breast Cancer Symposium suggest that the class of bone drugs known as bisphosphonates may reduce the risk of breast cancer and may help to maintain bone density in breast cancer patients treated with aromatase... Continue Reading

More Management and Prevention of Bone Complications Supportive Care

Management and Prevention of Fatigue Supportive Care

Yoga Improves Sleep Quality in Cancer Survivors (September 11, 2013)

Cancer survivors who participated in a special yoga program reported better sleep quality and less reliance on sleep medication, according to the results of a study published in the Journal of Clinical Oncology. Sleep problems and fatigue are among the... Continue Reading

Exercise Reduces Cancer-Related Fatigue (November 30, 2012)

Aerobic exercise can relieve the fatigue associated with cancer and its treatment, according to an updated systematic review published in The Cochrane Library. Fatigue is one of the most common side effects of cancer and its treatment. There are many... Continue Reading

Yoga Improves Sleep and Quality of Life (May 26, 2010)

A four-week yoga program that included breathing, meditation, postures, and other techniques improved sleep and quality of life among cancer survivors. The results of this study will be presented at the 2010 annual meeting of the American Society of Clinical... Continue Reading

More Management and Prevention of Fatigue Supportive Care

Management and Prevention of Mucositis Supportive Care

Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (March 24, 2010)

Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology. Multiple... Continue Reading

Oral Spray Reduces Mouth Sores (July 21, 2009)

Among patients treated with radiation therapy for head and neck cancer, mouth sores (oral mucositis) were reduced by use of an oral spray containing epidermal growth factor (EGF). These results were published in Cancer. Mouth sores are one of the most... Continue Reading

More Management and Prevention of Mucositis Supportive Care

Management and Prevention of Nausea and Vomiting Supportive Care

Study Suggests Long-acting Patch that Prevents Nausea and Vomiting Can Be Given in Combination with Intravenous Medication (February 9, 2010)

Use of a combination of Sancuso® (granisetron transdermal system; a patch that delivers granisetron through the skin for up to five days) and intravenous granisetron appears to be safe and feasible. This approach may provide immediate and extended... Continue Reading

More Management and Prevention of Nausea and Vomiting Supportive Care

Management and Prevention of Neutropenia Supportive Care

Neulasta Significantly Reduces Febrile Neutropenia Among Colorectal Cancer Patients Receiving Chemotherapy Plus Avasatin (February 25, 2013)

Neulasta® (pegfilgrastim) significantly reduced the incidence of grade 3/4 febrile neutropenia among patients with locally advanced or metastatic colorectal cancer who received chemotherapy with FOLFOX or FOLFIRI followed by Avastin® (bevacizumab),... Continue Reading

Naproxen May Relieve Bone Pain Associated with Neulasta (August 2, 2012)

Twice-daily naproxen is effective in reducing the incidence and severity of bone pain associated with the use of Neulasta® (pegfilgrastim), according to the results of a study published in the Journal of Clinical Oncology. Neulasta is a blood cell growth... Continue Reading

Celebrities Stand Up to Cancer (September 14, 2009)

Celebrities and Amgen are joining forces to Stand Up to Cancer™—in the form of a public service campaign designed to educate cancer patients and caregivers about managing the increased risk of infection during cancer treatment. Chemotherapy is an... Continue Reading

Amgen Helps Reduce Out-of-pocket Costs for Neulasta® (July 3, 2009)

Amgen’s Neulasta FIRST STEP™ Program provides assistance to eligible, low-income, commercially-insured chemotherapy patients who need help with their co-insurance or co-payment requirement for Neulasta® (pegfilgrastim). Neulasta is a blood cell growth... Continue Reading

More Management and Prevention of Neutropenia Supportive Care

Management and Prevention of Thrombocytopenia Supportive Care

Nplate Produces Rapid Response in Adults with ITP (December 20, 2011)

Among adults with low platelet counts or bleeding symptoms from primary immune thrombocytopenia (ITP), treatment with Nplate® (romiplostim) produces a rapid increase in platelet counts. These results were presented at the 53rd Annual Meeting of the American... Continue Reading

Nplate Active for More than Five Years in Adults with Chronic ITP (December 13, 2010)

Nplate® (romiplostim) appears to maintain platelet counts among adult patients with chronic immune (idiopathic) thrombocytopenia purpura (ITP) for more than five years. These results were presented at the 52nd Annual Meeting and Exposition of the American... Continue Reading

Nplate Reduces Treatment Failure and Splenectomy in Patients with ITP (November 17, 2010)

Compared with standard therapies, Nplate® (romiplostim) appears to reduce the risk of treatment failure and need for splenectomy among adult patients with chronic immune thrombocytopenia (ITP). These results were published in the New England Journal... Continue Reading

Nplate Evaluated in Children with Chronic ITP (December 9, 2009)

Among children with chronic immune thrombocytopenic purpura (ITP; an autoimmune disorder characterized by low platelet counts), treatment with Nplate® (romiplostim) stimulates platelet production and appears to be well tolerated. These results were presented... Continue Reading

More Management and Prevention of Thrombocytopenia Supportive Care

Mantle Cell Non-Hodgkin's Lymphoma

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Acalabrutinib granted Breakthrough Therapy Designation for the Treatment of Mantle Cell Lymphoma (August 9, 2017)

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is a highly-selective, potent... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Imbruvica Approved for Mantle Cell Lymphoma (January 23, 2014)

The U.S. Food and Drug Administration (FDA) has approved Imbruvica™ (ibrutinib) for the treatment of patients with mantle cell lymphoma, a rare and aggressive type of blood cancer. Non-Hodgkin’s lymphoma (NHL) is a form of cancer that begins in the... Continue Reading

More Mantle Cell Non-Hodgkin's Lymphoma

Melanoma

Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma (January 15, 2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma (January 12, 2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment... Continue Reading

FDA Approves Opdivo for Adjuvant Treatment of Melanoma (January 9, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with... Continue Reading

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers (January 8, 2018)

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical... Continue Reading

Opdivo Proves Superior to Yervoy for Adjuvant Treatment of Stage III-IV Melanoma (September 28, 2017)

Adjuvant treatment with the immunotherapy drug Opdivo (nivolumab) is superior to Yervoy (ipilimumab) for the management of stage IIIb/c or stage IV melanoma following complete surgical resection. These important results were presented at the European... Continue Reading

More Melanoma

Mesothelioma

Keytruda Shows Promise in Treatment of Mesothelioma (April 4, 2017)

Keytruda (pembrolizumab), an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

More Mesothelioma

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer (January 9, 2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior... Continue Reading

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (October 26, 2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The... Continue Reading

More Metastatic Breast Cancer

Metastatic Stage IV (D) Prostate Cancer

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (July 26, 2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (October 29, 2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

Prostvac® Vaccine Promising in Treatment of Metastatic Castration-Resistant Prostate Cancer (June 1, 2015)

The prostate cancer vaccine Prostvac® (rilimogene galvacirepvec/rilimogene glafolivec) may be active in combination with Yervoy® (ipilimumab) in the treatment of metastatic prostate cancer that does not respond to hormone therapy. These findings were... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology... Continue Reading

More Metastatic Stage IV (D) Prostate Cancer

Metastatic/Stage IVB Cervical Cancer

Avastin Improves Outcomes for Women with Advanced Cervical Cancer (June 11, 2013)

In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

Avastin Improves Outcomes for Women with Advanced Cervical Cancer (June 10, 2013)

In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

January Is National Cervical Cancer Awareness Month (March 8, 2009)

January Is National Cervical Cancer Awareness Month As the month of January brings cervical cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment... Continue Reading

Updates in the Management of Gynecologic Cancers (May 27, 2008)

Updates in the Management of Gynecologic Cancers: A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists The 39th Annual Meeting of the Society of Gynecologic Oncologists (SGO) was held in Tampa, Florida, from March 9 to 12, 2008,... Continue Reading

More Metastatic/Stage IVB Cervical Cancer

Miscellaneous

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

More Miscellaneous

Multiple Myeloma

Xgeva Approved for The Treatment of Multiple Myeloma (January 17, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma (December 13, 2017)

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are... Continue Reading

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor (November 20, 2017)

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people... Continue Reading

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns (September 25, 2017)

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab)... Continue Reading

Four-Year Follow-up with Empliciti Plus Revlimid in Patients with Advanced Multiple Myeloma Shows Long-term Beneift (July 13, 2017)

Four-year follow-up data from the Phase 3 ELOQUENT-2 clinical trial in which Empliciti (elotuzumab) plus Revlimid (lenalidomide) continued to demonstrate effectiveness in patients with relapsed/refractory multiple myeloma compared to patients treated... Continue Reading

More Multiple Myeloma

Myelodysplastic Syndrome

FDA Approves Vyxeos for Adults with Poor Prognosis AML (August 7, 2017)

The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes... Continue Reading

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome (February 21, 2017)

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation... Continue Reading

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (August 31, 2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents.... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT) (December 14, 2015)

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to... Continue Reading

More Myelodysplastic Syndrome

Myeloproliferative Neoplasms MPN

Long Term Follow Up Shows Durability of Jakafi® Response in Patients with Polycythemia Vera (December 27, 2017)

CancerConnect News: Jakafi® (ruxolitinib) was initially reported to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than the best available therapy at the 56th American Hematology Society Annual Meeting in 2014.1,2... Continue Reading

Fedratinib May Represent New Option for Jakafi-Resistant Myelofibrosis (December 6, 2017)

Patients with myelofibrosis resistant or intolerant to Jakafi (ruxolitinib) may have an alternative treatment option with a novel JAK2-selective inhibitor fedratinib, according to the results of clinical study recently published in the medical journal... Continue Reading

Incyte Announces Initiation of Clinical Trial Evaluating Jakafi® for the Treatment of Essential Thrombocythemia (November 22, 2017)

Incyte Corporation announced that the first patient has been treated in the RESET pivotal trial evaluating Jakafi®  (ruxolitinib) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant... Continue Reading

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis (December 20, 2016)

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly,... Continue Reading

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia (December 16, 2016)

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms... Continue Reading

More Myeloproliferative Neoplasms MPN

N

Sorry, there are no articles available for this cancer stage.

More N

Neuroblastoma

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Unituxin® Approved for Treatment of Children with High-Risk Neuroblastoma (April 9, 2015)

The U.S. Food and Drug Administration (FDA) has announced the first-ever drug approval for the treatment of children with high-risk neuroblastoma. In clinical trials Unituxin® (dinutuximab) has improved survival among children with this type of cancer... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

More Neuroblastoma

News

Rubraca Significantly Improves Survival Ovarian Cancer (January 18, 2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading

Xgeva Approved for The Treatment of Multiple Myeloma (January 17, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer (January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading

Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy (January 16, 2018)

CancerConnect News:  All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer (January 15, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified... Continue Reading

More News

Non-Hodgkin's Lymphoma

FDA approves Gazyva for previously untreated follicular lymphoma (January 11, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment... Continue Reading

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF) (November 15, 2017)

-MF and pcALCL Represent the Most Common Subtypes of Cutaneous T-Cell Lymphoma (CTCL)- -FDA Approval Based on Clinical Trial Results from the Phase 3 ALCANZA and Phase 2 Investigator-Sponsored Studies in CTCL- “Cutaneous T-cell lymphoma is a blood cancer... Continue Reading

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma (November 6, 2017)

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive... Continue Reading

Keytruda® Significantly Prolongs Survival Compared to Chemotherapy First-Line Treatment for Advanced Non-Small Cell Lung Cancer (October 23, 2017)

Updated study results presented at the World Congress on Lung Cancer this week continue to demonstrate that treatment of advanced non small cell lung cancer (NSCLC) whose tumors expressed high levels of PD-1 with Keytruda® (pembrolizumab) is superior... Continue Reading

More Non-Hodgkin's Lymphoma

O

Sorry, there are no articles available for this cancer stage.

More O

Osteosarcoma

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Do Complementary Therapies Work? – Ask the expert about herbs, acupuncture, and other complementary therapies (November 4, 2011)

Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service; Laurance S. Rockefeller Chair Integrative Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), click here for Dr. Cassileth’s bio Dr. Cassileth is a world-renowned... Continue Reading

Clinical Trial Participation Is Inadequate (August 31, 2011)

A large proportion of cancer patients do not enroll in clinical trials, and those who do participate may not adequately represent age groups, cancer stages, cancer types, and racial and ethnic groups. These findings were recently reported in the Annals... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Survivors of Childhood Cancer Face Risk of More Cancer (July 11, 2011)

Children who survive cancer have an increased risk of developing cancer later in life. These findings were recently reported in the Journal of Clinical Oncology. The good news about childhood cancer is that increasingly more children are surviving. These... Continue Reading

More Osteosarcoma

Other News Topics (not Types of Cancer)

FDA and CMS Collaborate to Make Novel Cancer Biomarker Test Available (December 7, 2017)

The U.S. Food and Drug Administration (FDA) has approved the F1CDx biomarker test designed to detect mutations in 324 genes and two genomic signatures in cancer patients. In a truly collaborative effort between the FDA and The Centers for Medicare &... Continue Reading

New Study Suggests Most Cancers are Unavoidable Irrespective of Life Style (July 19, 2017)

Two thirds of cancers are unavoidable even if you live a healthy life, according to a study published by doctors from John Hopkins.  The research, published in the journal Science, indicates that the majority of cancer-causing mutations are due to DNA... Continue Reading

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed (April 21, 2017)

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Xermelo-new option for controlling symptoms of Carcinoid Syndrome (March 1, 2017)

The US Food and Drug Administration (FDA) today approved the oral therapy Xermelo (telotristat ethyl) to be used in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea. Carcinoid syndrome is... Continue Reading

More Other News Topics (not Types of Cancer)

Ovarian Cancer

Rubraca Significantly Improves Survival Ovarian Cancer (January 18, 2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading

Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy (January 16, 2018)

CancerConnect News:  All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 11, 2017)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Endometriosis Patients are at Increased Risk for Ovarian Cancer, Study Confirms (May 3, 2017)

A large study based on the Nurses’ Health confirms that endometriosis is associated with increased risk of ovarian cancer.  Moreover, it further clarifies that this condition is not linked to a greater risk for endometrial cancer. Many women with endometriosis... Continue Reading

More Ovarian Cancer

P

Sorry, there are no articles available for this cancer stage.

More P

Pain Management Supportive Care

Over Regulation of Opioids May Leave Cancer Patients in Pain (December 2, 2013)

A worldwide trend toward over-regulation of opioid-based painkillers such as morphine and fentanyl is leaving billions of cancer patients to suffer intolerable pain, according to the results of a study published in the Annals of Oncology. Many cancer... Continue Reading

Antidepressant Cymbalta May Reduce Pain from Chemotherapy-Induced Peripheral Neuropathy (May 24, 2013)

The antidepressant Cymbalta® (duloxetine) appears to reduce the numbness and tingling associated with taxane or platinum-based chemotherapy, according to the results of a study published in the Journal of the American Medical Association. Peripheral... Continue Reading

Acupuncture Relieves Pain, Improves Functioning After Neck Surgery (April 29, 2010)

Acupuncture may reduce pain and improve functioning among patients with cancer who have undergone surgery to the neck, according to a study published in the Journal of Clinical Oncology.[1] As well, acupuncture may relieve xerostomia (dry mouth) among... Continue Reading

Onsolis Approved for Breakthrough Pain (July 28, 2009)

Onsolis (fentanyl buccal soluble film) has been approved by the U.S. Food and Drug Administration for the treatment of breakthrough cancer pain.[1] Pain may be a side effect of cancer treatment or may be caused by the cancer itself. If not adequately... Continue Reading

More Pain Management Supportive Care

Pancreatic Cancer

Diagnosed with Pancreatic Cancer: 10 Tips on How to Get The Most From Your Doctor (December 26, 2017)

1) Choose Your Doctor Carefully Surgeons, medical oncologists and radiation oncologists are the primary doctors involved with pancreatic cancer and often work in collaboration. Pick your primary oncologist carefully, rely on people you trust including... Continue Reading

Clinical Data on Immunotherapy AM0010 in Advanced Pancreatic Cancer Promising (July 11, 2017)

ARMO BioSciences, Inc., a late-stage immuno-oncology company, announced clinical data on its lead investigational immuno-oncology drug AM0010 (pegilodecakin, PEGylated Interleukin-10) at the ESMO 19th World Congress on Gastrointestinal Cancer, taking... Continue Reading

Preliminary Results Suggest That Pamrevlumab is Promising in Pancreatic Cancer (March 2, 2017)

Updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with standard-of-care chemotherapy in patients with locally advanced pancreatic ductal adenocarcinoma were presented during the ASCO 2017 Gastrointestinal Cancers Symposium... Continue Reading

Proton beam therapy may improve outcomes for pancreatic cancer (February 17, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

More Pancreatic Cancer

Progressive Relapsed Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma (October 6, 2015)

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the... Continue Reading

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma (April 28, 2015)

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer... Continue Reading

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 23, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th... Continue Reading

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma (December 18, 2014)

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of... Continue Reading

More Progressive Relapsed Hodgkin's Lymphoma

Prostate Cancer

Two Advances in Prostate Cancers You Might Not Know About (September 8, 2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (July 12, 2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (June 7, 2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months... Continue Reading

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (February 23, 2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of... Continue Reading

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10... Continue Reading

More Prostate Cancer

Q

Sorry, there are no articles available for this cancer stage.

More Q

R

Sorry, there are no articles available for this cancer stage.

More R

Radiopharmaceutical

Sorry, there are no articles available for this cancer stage.

More Radiopharmaceutical

Rectal Cancer

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer (October 16, 2017)

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic sequencing to determine if they have treatable targets is increasingly important to ensure patients... Continue Reading

NSAIDs Decrease Risk of Colorectal Cancer (September 18, 2017)

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively... Continue Reading

Proton Beam Therapy may Improve Outcomes for Rectal Cancer (March 6, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer (May 11, 2016)

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently... Continue Reading

More Rectal Cancer

Recurrent Anal Cancer

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Recurrent Anal Cancer

Recurrent Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

More Recurrent Bladder Cancer

Recurrent Breast Cancer

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (June 30, 2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According... Continue Reading

More Recurrent Breast Cancer

Recurrent Cervical Cancer

Avastin Improves Outcomes for Women with Advanced Cervical Cancer (June 11, 2013)

In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

Avastin Improves Outcomes for Women with Advanced Cervical Cancer (June 10, 2013)

In a Phase III clinical trial, adding Avastin® (bevacizumab) to chemotherapy prolonged overall survival among women with recurrent or metastatic cervical cancer. These results were presented at the 2013 Annual Meeting of the American Society of Clinical... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Avastin® Shows Promise in Treatment of Cervical Cancer (March 8, 2009)

Avastin® Shows Promise in Treatment of Cervical Cancer According to the results of a Phase II clinical trial, the targeted therapy Avastin® (bevacizumab) warrants further investigation in the treatment of persistent or recurrent squamous cell carcinoma... Continue Reading

January Is National Cervical Cancer Awareness Month (March 8, 2009)

January Is National Cervical Cancer Awareness Month As the month of January brings cervical cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment... Continue Reading

More Recurrent Cervical Cancer

Recurrent Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

More Recurrent Gastric Cancer

Recurrent Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Recurrent Liver Cancer

Recurrent Lung Cancer - Non-Small Cell

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (June 7, 2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

Recurrent Lung Cancer - Small Cell

Advanced Squamous Cell Lung Cancer: The Lung-MAP Trial (January 13, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Innovative Clinical Trials for Lung Cancer Currently Underway (January 7, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

Xgeva Improves Survival Over Zometa in Advanced Lung Cancer (November 28, 2012)

Patients with advanced lung cancer experienced modest improvement in survival when they received bone-targeted therapy with Xgeva® (denosumab) instead of Zometa® (zoledronic acid), according to the results of a study published in the Journal of Thoracic... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

November Is National Lung Cancer Awareness Month (November 6, 2009)

As the month of November brings lung cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated lung cancer information... Continue Reading

More Recurrent Lung Cancer - Small Cell

Recurrent Melanoma

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

Coffee May Decrease Risk of Melanoma Skin Cancer (February 2, 2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated with ipilimumab... Continue Reading

More Recurrent Melanoma

Recurrent Multiple Myeloma

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Aplidin® Improves Progression-Free Survival in Multiple Myeloma (April 21, 2016)

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone among patients with multiple myeloma that has progressed following... Continue Reading

Combo Therapy of Kyprolis plus Dexamethasone Approved for Recurrent Multiple Myeloma (January 26, 2016)

The United States Food and Drug Administration (FDA) recently approved a new treatment combination consisting of Kyprolis (carfilzomib) plus dexamethasone for patients with relapsed or refractory multiple myeloma. Multiple myeloma is a type of blood cancer... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

More Recurrent Multiple Myeloma

Recurrent Non-Hodgkin's Lymphoma

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Adding Revlimid to R-CHOP May Improve Outomes of Selected Patients with NHL (September 4, 2014)

The results of a recently completed study reported in the Journal of Clinical Oncology indicate that the addition of Revlimid® (lenalidomide) to R-CHOP the standard treatment for non hodgkin lymphoma (NHL) can overcome the negative prognostic effect... Continue Reading

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI) (September 3, 2014)

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

More Recurrent Non-Hodgkin's Lymphoma

Recurrent Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

More Recurrent Ovarian Cancer

Recurrent Pancreatic Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (September 23, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

More Recurrent Pancreatic Cancer

Recurrent Testicular Cancer

Testicular Cancer Rates on the Rise (June 24, 2013)

The incidence of testicular cancer continued to rise in the United States over the past decade, most notably among Hispanic men, according to the results of a study presented at the annual meeting of the American Urological Association in San Diego, California.... Continue Reading

Marijuana May Increase Risk of Testicular Cancer (September 21, 2012)

Recreational marijuana use may increase the risk of developing subtypes of testicular cancer that have a worse prognosis, according to the results of a study published early online in the journal Cancer. Testicular cancer is the most common cancer diagnosed... Continue Reading

Paclitaxel/Gemzar Provides Long-Term Survival in Refractory Testicular Cancer (June 14, 2011)

Treatment with the chemotherapy agents paclitaxel and Gemzar® (gemcitabine) provides long-term survival and possible cure among some patients with testicular cancer that has stopped responding to prior therapies. These results were recently presented... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Recurrent Testicular Cancer

Recurrent Uterine Cancer

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers (March 8, 2009)

Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective... Continue Reading

More Recurrent Uterine Cancer

Recurrent/Relapsed Rectal Cancer

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer (March 17, 2015)

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal... Continue Reading

Encouraging Overall Survival and Well-Being for Xilonix™ in Advanced Colorectal Cancer (February 19, 2015)

The investigational agent Xilonix™ appears safe and effective for patients with advanced colorectal cancer. These findings were presented at the 2015 Gastrointestinal Cancers Symposium, January 15–17, in San Francisco, California.[1] According to... Continue Reading

Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer (January 16, 2015)

The results of an international phase III study evaluating 1,072 patients with advanced colorectal cancer whose disease progressed on or after initial therapy will be presented at the upcoming Gastrointestinal Symposium in San Francisco. The trial results... Continue Reading

More Recurrent/Relapsed Rectal Cancer

Refactory/Recurrent Prostate Cancer

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer (June 13, 2016)

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (February 22, 2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (November 4, 2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients (February 23, 2015)

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology... Continue Reading

Xofigo Extends Survival in Hormone-Refractory Prostate Cancer (November 6, 2014)

For patients with advanced hormone-refractory prostate cancer, the agent Xofigo® (radium-223) appears similarly effective in patients who have and have not received Taxotere® (docetaxel), a chemotherapy drug that can be used in the treatment of advanced... Continue Reading

More Refactory/Recurrent Prostate Cancer

Renal Cancer

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma (January 5, 2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma... Continue Reading

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer (November 9, 2017)

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to... Continue Reading

FDA Fast Track Designation Granted To CB-839 For Treatment Of Patients With Renal Cell Carcinoma (June 19, 2017)

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-839 in combination with afinitor® (everolimus), for the treatment of patients with metastatic renal cell carcinoma who have received 2 or more prior lines of therapy. ... Continue Reading

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer (March 1, 2017)

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical... Continue Reading

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer (December 5, 2016)

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical... Continue Reading

More Renal Cancer

Retinoblastoma

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Retinoblastoma

S

Sorry, there are no articles available for this cancer stage.

More S

Sarcoma

Roadmap to Personalized Therapies for Sarcoma and other Aggressive Cancers (August 8, 2017)

Sarcoma is a rare and deadly form of cancer occurring in the bones and connective tissue that affects individuals of all ages. Its aggressiveness, rarity and diversity continue to hinder efforts to identify effective therapies for people with this malignancy.... Continue Reading

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Regional Chemotherapy Technique for Extremity Sarcoma Salvages Patients’ Limbs from Amputation (March 16, 2017)

Patients with a type of advanced malignant cancer of the arms or legs have typically faced amputation of the afflicted limb as the only treatment option.  However, a technique that limits the application of chemotherapy to the cancerous region can preserve... Continue Reading

Chemotherapy Before Surgery Improves Treatment of Sarcoma (November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is... Continue Reading

Halaven Approved for Liposarcoma (February 4, 2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading

More Sarcoma

Screening/Prevention Anal Cancer

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

Anal Cancer Rates Appear to Be On the Rise in the U.S. (May 6, 2013)

The number of people in the United States with anal cancer has tripled since the 1970s, according to the results of a study published in the Journal of Clinical Oncology. Anal cancer is an uncommon type of cancer that occurs in the anal canal, the opening... Continue Reading

Anal Cancer on the Rise in Men with HIV (October 15, 2012)

Nearly one-third of men with anal cancer have the human immunodeficiency virus (HIV), according to the results of a study published in the Journal of the National Cancer Institute. Anal cancer is an uncommon type of cancer that occurs in the anal canal,... Continue Reading

HPV Vaccine Reducing Infection among Vaccinated and Unvaccinated (July 16, 2012)

The human papillomavirus (HPV) vaccine is reducing infections of virus strains associated with genital warts and cancer, even among those who remain unvaccinated, according to the results of a study published in Pediatrics. HPV is the most common sexually... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening/Prevention Anal Cancer

Screening/Prevention Bladder Cancer

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

More Evidence that Diabetes Drugs Increase Risk of Bladder Cancer (August 22, 2012)

A popular class of diabetes drugs called thiazolidinediones (TZDs) increases the risk of bladder cancer, according to the results of a study published early online in the Journal of the National Cancer Institute. Bladder cancer is diagnosed in as many... Continue Reading

Diabetes Drugs May Increase Risk of Bladder Cancer (July 26, 2012)

A class of drugs called thiazolidinediones has been linked to an increased risk of bladder cancer among adults with type 2 diabetes, according to a study published early online in the Canadian Medical Association Journal. Bladder cancer is diagnosed... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Bladder Cancer

Screening/Prevention Breast Cancer

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

3D Mammography Proves More Accurate in Breast Cancer Detection (March 31, 2016)

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading

More Screening/Prevention Breast Cancer

Screening/Prevention Cervical Cancer

The HPV Vaccine Prevents Lesions That Could Cause Cervical Cancer by 50 Percent (October 13, 2016)

A recent report published online Sept. 29 in the journal JAMA Oncology suggests that the vaccine against human papillomavirus (HPV) infection, which doctors believe causes most cases of cervical cancer, is more effective than previously thought. Human... Continue Reading

HPV Testing Found to Be More Effective Than Pap Smears in Evaluating Cervical Cancer Risk (July 23, 2014)

Researchers at the National Cancer Institute reported that testing for HPV (human papillomavirus) is the most effective way to determine whether a woman is at risk for developing cervical cancer in the near future. Specifically, the study found that negative... Continue Reading

Gardasil Provides Poor Protection in Women Over 18 (February 3, 2014)

A significant percentage of women vaccinated with Gardasil® (quadrivalent human papillomavirus recombinant vaccine) may not be protected against high-grade squamous intraepithelial lesions (HSIL) and lesser dysplasia—especially if they were vaccinated... Continue Reading

Younger Girls May Need Fewer Gardasil Shots (June 26, 2013)

Two doses of the human papillomavirus (HPV) vaccine Gardasil may be just as effective in younger girls (preteens) as the recommended three doses given to older teens, according to the results of a study published in the Journal of the American Medical... Continue Reading

HPV Test Appropriate After Indeterminate Pap Test (April 29, 2013)

Women who have an indeterminate Pap smear should undergo human papillomavirus (HPV) testing rather than another Pap smear, according to the results of Cochrane Review. Cancer screening refers to the use of tests to detect cancer in individuals who do... Continue Reading

More Screening/Prevention Cervical Cancer

Screening/Prevention Colon Cancer

Inflammatory Bowel Disease: More Common than Previously Thought (November 8, 2016)

A recent report reveals that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), effect an estimated 3.1 million (1.3%) U.S. adults.  This is an increase from a report released in 1999 estimating that 1.8... Continue Reading

New Treatment May Reduce Precancerous Polyps in Both Large and Small Intestine in Hereditary Cancer Patients (May 26, 2016)

A new study published in the Journal of the American Medical Association (JAMA), has reported a new prevention treatment for individuals at high risk of developing colon cancer due to the APC (adenomatous polyposis coli) gene. Inheriting a mutation in... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

More Screening/Prevention Colon Cancer

Screening/Prevention Esophageal Cancer

It’s GERD Awareness Week–November 20th (November 20, 2016)

It’s that time of year again when there is a tendency to overindulge in a mélange of delicious foods. Although many people may only suffer discomfort from over eating, another group of people suffer from the far more troublesome and chronic disorder... Continue Reading

Regular Screening of Barrett’s Esophagus Patients Improves Rate of Early Cancer Detection (May 12, 2015)

Patients with Barrett’s esophagus who undergo regular exams have an improved chance that precancerous changes and esophageal cancer will be detected early. These findings were published in the journal Gut. Barrett’s esophagus is a pre-cancerous condition... Continue Reading

Radiofrequency Ablation in Barrett’s Esophagus May Prevent Esophageal Cancer (April 15, 2015)

Treatment of Barrett’s esophagus with radiofrequency ablation appears to keep the condition from progressing to esophageal cancer. These findings were published in the Journal of the American Medical Association. Barrett’s esophagus is a pre-cancerous... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (August 18, 2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk... Continue Reading

Esophageal Cancer on the Rise (November 12, 2012)

The rate of esophageal cancer is on the rise worldwide, according to the results of a study published in GUT: An International Journal of Gastroenterology and Hepatology, but the onset and magnitude of the increase varies among countries and even states. The... Continue Reading

More Screening/Prevention Esophageal Cancer

Screening/Prevention Gastric Cancer

Gastric Cancer Risk Factors You Need to Know (February 8, 2016)

Successful treatment for stomach or gastric cancer starts with early detection. Most cases of stomach cancer are diagnosed in the advanced stages as there is no routine test for early detection. This makes it very important for people to know their risk... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

Scientific Review Suggests Aspirin Significantly Cuts Cancer Rates (August 18, 2014)

A recent review of several studies confirms that taking a small daily dose of aspirin significantly reduces the risk of developing – or dying from several kinds of cancer.(1) Several clinical studies have suggested that aspirin can reduce the risk... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Gastric Cancer

Screening/Prevention Leukemia

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Childhood CT Scans Linked to Leukemia and Brain Cancer Later in Life (June 20, 2012)

Children and young adults who undergo multiple computed tomography (CT) scans have an increased risk of leukemia and brain tumors in the decade following their first scan, according to the results of a study published in The Lancet. CT scans are a common... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Greater Cancer Risk Among Taller Women (July 28, 2011)

Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading

More Screening/Prevention Leukemia

Screening/Prevention Liver Cancer

Infection with Hepatitis C Increases Risk of Cirrhosis (March 10, 2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (July 31, 2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Coffee Cuts Risk of Liver Cancer (November 8, 2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

Statins Linked to Lower Risk of Liver Cancer in Hepatitis C (May 8, 2013)

People infected with chronic hepatitis C are less likely to develop liver cancer if they are taking statins (cholesterol-lowering drugs), according to the results of a study published in the Journal of Clinical Oncology.[1] The liver is the largest organ... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening/Prevention Liver Cancer

Screening/Prevention Lung Cancer - Non-Small Cell

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung... Continue Reading

Screening Could Reduce Lung Cancer Mortality (April 24, 2013)

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading

Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)

Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading

Female Lung Cancer Deaths on the Rise in Some Areas (July 3, 2012)

Lung cancer deaths are on the rise among young and middle-aged white women, mainly in the South and the Midwest, according to a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death among both men and... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Screening/Prevention Lung Cancer - Small Cell

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung... Continue Reading

Screening Could Reduce Lung Cancer Mortality (April 24, 2013)

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading

Female Lung Cancer Deaths on the Rise in Some Areas (July 3, 2012)

Lung cancer deaths are on the rise among young and middle-aged white women, mainly in the South and the Midwest, according to a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death among both men and... Continue Reading

Diesel Exhaust Linked to Lung Cancer (June 26, 2012)

Diesel exhaust is associated with an increased risk of lung cancer, according to a press release issued by the World Health Organization (WHO).[1] The announcement came after a group of international experts gathered for a weeklong meeting to review the... Continue Reading

More Screening/Prevention Lung Cancer - Small Cell

Screening/Prevention Melanoma

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

MRA Applauds Congress for Getting the Sunscreen Innovation Act over the Goal Line (November 17, 2014)

(OMNI-CancerConnect) — The Melanoma Research Alliance (MRA) applauds the House for acting on the Senate-passed Sunscreen Innovation Act, clearing the way for the President’s signature. Thanks to the leadership and hard work of Congressmen Ed Whitfield... Continue Reading

Viagra Associated with Increased Risk of Melanoma (April 18, 2014)

Men who take by Viagra (sildenafil) are 84 percent more likely to develop melanoma than men who do not, according to the results of a study published in JAMA Internal Medicine. Melanoma is a potentially fatal type of skin cancer that begins in the melanocytes,... Continue Reading

More Screening/Prevention Melanoma

Screening/Prevention Non-Hodgkin's Lymphoma

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers hare found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (September 4, 2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Organ Transplant Recipients Have Increased Cancer Risk (November 9, 2011)

People who have received a solid organ transplant (such as a kidney or liver) are twice as likely as people in the general population to develop cancer. These results were published in the Journal of the American Medical Association. In 2010, more than... Continue Reading

Greater Cancer Risk Among Taller Women (July 28, 2011)

Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading

More Screening/Prevention Non-Hodgkin's Lymphoma

Screening/Prevention Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (October 6, 2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Personalized Screening Test for Ovarian Cancer Potentially Game-Changing, says GlobalData (May 18, 2015)

   LONDON, UK (GlobalData), 12 May 2015 – The encouraging recent results of a 14-year study by the UK Collaborative Trial of Ovarian Cancer Screening could herald a radical departure from the approach established by other screening tests for... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

More Screening/Prevention Ovarian Cancer

Screening/Prevention Pancreatic Cancer

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (August 6, 2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were... Continue Reading

Aspirin Reduces Risk of Pancreatic Cancer (July 1, 2014)

The results of a recent study suggest that regular aspirin use reduces the risk of pancreatic cancer by half.  Clinical studies have also found that regular aspirin use can reduce the risk for colon, esophageal, lung and prostate cancers, as well as... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Pancreatic Cancer

Screening/Prevention Prostate Cancer

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (August 15, 2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Omega-3 Fatty Acids Linked to Increased Risk of Prostate Cancer (August 23, 2013)

Omega-3 fatty acids may be linked to an increased risk of prostate cancer, according to the results of a study published in the Journal of the National Cancer Institute. Other than skin cancer, prostate cancer is the most commonly diagnosed cancer in... Continue Reading

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

Aspirin and Cancer Risk and Mortality (September 17, 2012)

Aspirin and cancer risk is in the news again—and the link is still unclear. Two studies published early online in the Journal of Clinical Oncology evaluated the relationship between aspirin and cancer risk—one indicated that aspirin does not appear... Continue Reading

More Screening/Prevention Prostate Cancer

Screening/Prevention Rectal Cancer

EPI proColon® – Novel Blood Screening Test Approved for Colorectal Cancer Detection (May 2, 2016)

The United States Food and Drug Administration (FDA) has approved Epi proColon®, a test that screens for colorectal cancer from a simple blood draw. The approval specifies that EPI proColon is only indicated for individuals at an average risk of developing... Continue Reading

Anesthesia Increases Colonoscopy Risks (March 4, 2016)

Though colonoscopy is often performed with anesthesia, a recent study published in the journal Gastroenterology has found that sedation increases the risk of complications.1 A colonoscopy is a type of exam that a doctor uses to check the lining of the... Continue Reading

Does Processed Meat Cause Colorectal Cancer? (November 16, 2015)

According to the International Agency for Research on Cancer (IARC), eating processed meat products can increase a person’s risk for developing colorectal cancer. Processed meat is classified as meat that has been salted, cured, fermented, or smoked... Continue Reading

Cancers Caught During Screening Colonoscopy are More Survivable (July 21, 2015)

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test, according to a study in the July issue of GIE: Gastrointestinal Endoscopy,... Continue Reading

Stool Test Spots Most Colon Cancers (February 19, 2014)

A stool test known as the fecal immunochemical test (FIT) is accurate in diagnosing most colorectal cancers, according to a meta-analysis published in the Annals of Internal Medicine. Screening is crucial for the prevention and early detection of colorectal... Continue Reading

More Screening/Prevention Rectal Cancer

Screening/Prevention Uterine Cancer

Weighing the Risks (August 12, 2014)

Exploring the Link Between Obesity and Cancer By Kari Bohlke, ScD “For the great majority of Americans who do not use tobacco, weight control, dietary choices, and levels of physical activity are the most important modifiable determinants of cancer... Continue Reading

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Lynch Syndrome Also Linked with Breast and Pancreatic Cancer (February 17, 2012)

A study of families with Lynch Syndrome has expanded the list of cancers related to the condition: carriers of a Lynch Syndrome gene mutation also appear to have an increased risk of breast cancer and pancreatic cancer. These results were published in... Continue Reading

More Screening/Prevention Uterine Cancer

Skin Cancer

Start 2018 Right: Plan for Cancer Screening and Save Lives! (January 5, 2018)

Screening guidelines should initiate conversations with your healthcare team.  Charles H Weaver MD, Editor CancerConnect CancerConnect News: The goal of cancer screening is to find disease at early stages in people who are otherwise asymptomatic—before... Continue Reading

Skin Cancer Prevention Tips from the Skin Cancer Foundation (May 17, 2017)

The development of skin cancer is certainly a risk for any individual, but particularly for those of us who spend time in the outdoors. As summer approaches it’s important to keep in mind that by taking certain steps to protect yourself from the sun,... Continue Reading

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

FDA Approves Bavencio as First Treatment for Merkel Cell Cancer (March 31, 2017)

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

More Skin Cancer

Skin Cancer Overview

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each... Continue Reading

Surgery May Not Be Best in Elderly Patients with Nonfatal Skin Cancer (June 28, 2013)

Although skin cancer is often treated with surgery, older patients with a limited life expectancy may not benefit from this treatment approach because they may endure complications and not live long enough to benefit from the treatment, according to the... Continue Reading

More Skin Cancer Overview

Soft Tissue Sarcomas

Chemotherapy Before Surgery Improves Treatment of Sarcoma (November 7, 2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is... Continue Reading

Halaven Approved for Liposarcoma (February 4, 2016)

The United States Food and Drug Administration (FDA) has approved the chemotherapy agent Halaven (eribulin) for the treatment of liposarcoma. It’s the first drug approved for liposarcoma that has demonstrated an improvement in overall survival. Halaven... Continue Reading

Yondelis® Approved for Treatment of Soft Tissue Sarcoma (November 2, 2015)

The United States Food and Drug Administration (FDA) approved the chemotherapy agent, Yondelis® (trabectedin), for the treatment of liposarcoma and leiomyosarcoma—two types of soft-tissue sarcomas.1 The approval of Yondelis is for patients whose cancer... Continue Reading

Yondelis® Bests Standard Therapy in Liposarcoma and Leiomyosarcoma (October 20, 2015)

The chemotherapy agent, Yondelis® (trabectedine), improves outcomes compared to the standard agent, DTIC (dacarbazine), in patients with advanced liposarcoma or leiomyosarcoma that has recurred or progressed following prior therapies. These results were... Continue Reading

Longer Overall Survival for Patients with Soft Tissue Sarcoma Treated with Halaven® (June 11, 2015)

Halaven® (eribulin) may extend overall survival in patients with previously treated, advanced soft tissue sarcoma (STS). These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois)... Continue Reading

More Soft Tissue Sarcomas

Stage I Cervical Cancer

Sentinel Node Biopsy Is a Minimally-invasive, Effective Method for Determining Spread of Cervical Cancer (June 9, 2009)

Sentinel Node Biopsy Is a Minimally-invasive, Effective Method for Determining Spread of Cervical Cancer The majority of women with cervical cancer can safely undergo sentinel node biopsy instead of full pelvic lymph node dissection to determine the spread... Continue Reading

January Is National Cervical Cancer Awareness Month (March 8, 2009)

January Is National Cervical Cancer Awareness Month As the month of January brings cervical cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment... Continue Reading

Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer (March 8, 2009)

Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer Robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications,... Continue Reading

Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers (March 8, 2009)

Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison... Continue Reading

Updates in the Management of Gynecologic Cancers (May 27, 2008)

Updates in the Management of Gynecologic Cancers: A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists The 39th Annual Meeting of the Society of Gynecologic Oncologists (SGO) was held in Tampa, Florida, from March 9 to 12, 2008,... Continue Reading

More Stage I Cervical Cancer

Stage I Node Negative Breast Cancer

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo (September 7, 2016)

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer (June 7, 2016)

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

More Stage I Node Negative Breast Cancer

Stage I Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (September 28, 2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the... Continue Reading

Aspirin as Ovarian Cancer Prevention? Research Says Maybe (February 20, 2014)

New evidence suggests that an aspirin a day may reduce the risk of ovarian cancer. But more research is needed before your doctor will routinely prescribe it for prevention. You may know that low doses of aspirin, taken daily, can help reduce the risk... Continue Reading

Ovarian Cancer Rates Declining in Breast Cancer Survivors (February 7, 2013)

The rate of second primary ovarian cancers after first primary breast cancer appears to be on the decline, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, roughly 22,000 women are diagnosed... Continue Reading

More Stage I Ovarian Cancer

Stage I-II Testicular Cancer

Testicular Cancer Rates on the Rise (June 24, 2013)

The incidence of testicular cancer continued to rise in the United States over the past decade, most notably among Hispanic men, according to the results of a study presented at the annual meeting of the American Urological Association in San Diego, California.... Continue Reading

Marijuana May Increase Risk of Testicular Cancer (September 21, 2012)

Recreational marijuana use may increase the risk of developing subtypes of testicular cancer that have a worse prognosis, according to the results of a study published early online in the journal Cancer. Testicular cancer is the most common cancer diagnosed... Continue Reading

Low-Dose CT Scans Effective for Surveillance of Early Testicular Cancer (June 15, 2011)

Low-dose computed tomography (CT) scans provide a reliable method for surveillance and reduce radiation exposure by 40-60% among patients with Stage I testicular cancer. These results were recently presented at the 2011 annual meeting of the American... Continue Reading

New Genes Linked to Testicular Cancer (June 28, 2010)

Scientists have discovered three new genes associated with testicular cancer, according to the results of a study published in Nature Genetics.[1] Testicular cancer is the most common type of cancer in men ages 15 to 45. The incidence of testicular cancer... Continue Reading

Men with Infertility May Have Increased Risk of Testicular Cancer (March 8, 2009)

Men with Infertility May Have Increased Risk of Testicular Cancer Men with infertility are three times more likely to develop testicular cancer compared with fertile men, according to the results of a study published in the Archives of Internal Medicine.[1] The... Continue Reading

More Stage I-II Testicular Cancer

Stage I/Smoldering Myeloma Multiple Myeloma

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes (February 3, 2017)

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were published in The Lancet Oncology, and presented at... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma (December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results... Continue Reading

Revlimid Linked with Second Primary Malignancies in Patients with Myeloma (March 7, 2014)

Revlimid® (lenalidomide)—particulary when used in combination with oral melphalan—is associated with an increased risk of second primary malignancies in patients with myeloma, according to the results of a study published in The Lancet Oncology. Multiple... Continue Reading

Early Treatment of Multiple Myeloma Slows Progression (August 30, 2013)

Early treatment with Revlimid® (lenalidomide) and dexamethasone for patients with high-risk smoldering multiple myeloma delays progression to active disease and increases overall survival, according to the results of a study published in the New England... Continue Reading

More Stage I/Smoldering Myeloma Multiple Myeloma

Stage II-IV Ovarian Cancer

Ovarian Cancer Clinical Trials: What, Where, Why (July 5, 2017)

Pre-recorded webinar on Thursday, July 13th, 7–8 p.m. EST Have questions about ovarian cancer clinical trials? Join the National Ovarian Cancer Coalition® (NOCC) for an Ask the Expert session with Michael J. Birrer, MD, PhD, recognized nationally... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a BRCA gene mutation. Each... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

More Stage II-IV Ovarian Cancer

Stage III Bladder Cancer

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer (March 31, 2015)

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Study Explores New Approach to Boosting the Immune System after Cancer Treatment (August 24, 2011)

Researchers are seeking participants for a Phase II clinical trial that will explore whether an investigational treatment can help the immune system recover after cancer treatment. Cancer treatments such as chemotherapy and radiation therapy often deplete... Continue Reading

More Stage III Bladder Cancer

Stage III Melanoma

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

More Stage III Melanoma

Stage III Testicular Cancer

Testicular Cancer Rates on the Rise (June 24, 2013)

The incidence of testicular cancer continued to rise in the United States over the past decade, most notably among Hispanic men, according to the results of a study presented at the annual meeting of the American Urological Association in San Diego, California.... Continue Reading

Marijuana May Increase Risk of Testicular Cancer (September 21, 2012)

Recreational marijuana use may increase the risk of developing subtypes of testicular cancer that have a worse prognosis, according to the results of a study published early online in the journal Cancer. Testicular cancer is the most common cancer diagnosed... Continue Reading

New Genes Linked to Testicular Cancer (June 28, 2010)

Scientists have discovered three new genes associated with testicular cancer, according to the results of a study published in Nature Genetics.[1] Testicular cancer is the most common type of cancer in men ages 15 to 45. The incidence of testicular cancer... Continue Reading

More Stage III Testicular Cancer

Stage IV (D)/Relapsed Colon Cancer

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (August 24, 2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (June 23, 2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University... Continue Reading

More Stage IV (D)/Relapsed Colon Cancer

Stage IV Anal Cancer

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (May 1, 2008)

No Benefit with Addition of Platinol® to Treatment for Anal Cancer Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published... Continue Reading

More Stage IV Anal Cancer

Stage IV Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (May 27, 2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (June 23, 2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (May 31, 2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug (May 2, 2011)

PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs for rare diseases by providing incentives for... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

More Stage IV Liver Cancer

Stage IV Melanoma

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

More Stage IV Melanoma

Stage IV Pancreatic Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led... Continue Reading

Onivyde Approved for Pancreatic Cancer (November 3, 2015)

The United States Food and Drug Administration (FDA) approved Onivyde (irinotecan liposome injection) to be used in combination with fluorouracil and leucovorin for patients with advanced pancreatic cancer. The approval is indicated for patients with... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

More Stage IV Pancreatic Cancer

Stage IV Rectal Cancer

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

Lonsurf® Approved for the Treatment of Colorectal Cancer (September 30, 2015)

The United States Food and Drug Administration (FDA) has approved the oral agent, Lonsurf® (trifluridine and tipiracil), for the treatment of colorectal cancer. Colorectal cancer remains the second leading cause of cancer-related deaths in the U.S. although... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (August 24, 2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (August 11, 2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment (June 23, 2015)

Metastatic colorectal cancer patients tend to live longer when they respond to the first line of chemotherapy their doctors recommend. To better predict how patients will respond to chemotherapy drugs before they begin treatment, researchers at University... Continue Reading

More Stage IV Rectal Cancer

Stage IV Uterine Cancer

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Risk Factors Identified for Uterine Sarcoma Survival (March 8, 2009)

Risk Factors Identified for Uterine Sarcoma Survival Survival for patients diagnosed with uterine leiomyosarcomas may be influenced by several factors. These findings were recently published in the journal Cancer. The uterus is located in the abdomen... Continue Reading

Updates in the Management of Gynecologic Cancers (May 27, 2008)

Updates in the Management of Gynecologic Cancers: A Report from the 39th Annual Meeting of the Society of Gynecologic Oncologists The 39th Annual Meeting of the Society of Gynecologic Oncologists (SGO) was held in Tampa, Florida, from March 9 to 12, 2008,... Continue Reading

More Stage IV Uterine Cancer

Stage IV/Metastatic Bladder Cancer

Tecentriq® Approved for Bladder Cancer (June 8, 2016)

The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved... Continue Reading

Tecentriq® Effective as Initial Therapy in Advanced Bladder Cancer (June 8, 2016)

The immunotherapy agent Tecentriq® (atezolizumab) provides anti-cancer activity when used as initial therapy among patients with advanced bladder cancer who are not able to tolerate standard therapy. These results were recently presented at the 2016... Continue Reading

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer (March 16, 2015)

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer (June 12, 2014)

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer... Continue Reading

More Stage IV/Metastatic Bladder Cancer

Stage IV/Recurrent Esophageal Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Patients Rising, Launched to Fight for Access to Vital Therapies and Services for Patients with Life-Threatening Diseases (August 25, 2015)

Patient advocacy veterans Jonathan and Terry Wilcox today announced the launch of a new not-for-profit organization, Patients Rising. This patient advocacy organization will educate, advocate and communicate the importance of access to vital therapies... Continue Reading

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers (February 12, 2015)

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity... Continue Reading

Esophageal Cancer Survival Improved Using Targeted Therapy Developed in Lung Cancer (December 4, 2014)

Targeted therapy commonly used in lung cancer improves survival of esophageal cancer patients according to clinical trial results recently presented at the National Cancer Research Institute (NCRI) Cancer Conference in the UK. The esophagus is a muscular... Continue Reading

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (November 13, 2014)

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved... Continue Reading

More Stage IV/Recurrent Esophageal Cancer

Stages 0-I Bladder Cancer

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

Study Compares Two Types of BCG for Bladder Cancer (April 10, 2012)

For non-muscle-invasive bladder cancer, use of theConnaughtstrain of bacillus Calmette-Guérin (BCG) may be more effective at preventing recurrences than the Tice strain of BCG. These results—from a Phase III clinical trial—were presented at the 2012... Continue Reading

More Stages 0-I Bladder Cancer

Stages I-II Anal Cancer

Intensity-Modulated Radiation Therapy Reduces Side Effects for Patients with Anal Cancer (January 31, 2011)

Treatment of anal cancer with chemotherapy and intensity-modulated radiation therapy (IMRT) may be as effective as treatment with conventional radiation and chemotherapy but with fewer side effects. These findings were presented at the eighth annual Gastrointestinal... Continue Reading

No Benefit with Addition of Platinol® to Treatment for Anal Cancer (May 1, 2008)

No Benefit with Addition of Platinol® to Treatment for Anal Cancer Addition of the drug Platinol® (cisplatin) to 5-FU (5-flourouracil), mitomycin, and radiation may not improve outcomes for patients with anal cancer. These findings were recently published... Continue Reading

More Stages I-II Anal Cancer

Stages I-II Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Reolysin® Receives FDA Designation for Gastric Cancer (May 14, 2015)

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The... Continue Reading

U.S. FDA Issues Warning about Certain Type of Endoscope (February 20, 2015)

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult... Continue Reading

Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer (September 25, 2012)

Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of Clinical Oncology.[1] Gastric cancer refers to cancer... Continue Reading

More Stages I-II Gastric Cancer

Stages I-II Melanoma

Check It Out: May is Skin Cancer Awareness Month (May 1, 2017)

Skin cancer is the most commonly diagnosed cancer in the United States. Although the majority of skin cancers fall under basal cell and squamous cell carcinomas (number of cases estimated to be around 5 million), most deaths are a result of melanoma which... Continue Reading

Injecting of PV-10 is Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal and squamous cell skin cancer are diagnosed each... Continue Reading

Melanoma More Deadly in Young White Men than Women (August 12, 2013)

Adolescent and young white men with melanoma are more than 50 percent more likely than their female counterparts to die from the disease, according to the results of a study published in JAMA Dermatology.[1] Melanoma is a deadly type of skin cancer that... Continue Reading

More Stages I-II Melanoma

Stages I-III Esophageal Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Minimally Invasive Endoscopic Procedure Effective in Early Esophageal Cancer (December 4, 2013)

A minimally invasive endoscopic procedure to remove superficial, early stage esophageal is as effective as surgery that removes the entire esophagus, according to the results of a study published in Clinical Gastroenterology and Hepatology. The esophagus... Continue Reading

Surgery Improves Survival in Esophageal Cancer (February 21, 2013)

Surgery after chemoradiotherapy—which is the standard of care in advanced esophageal cancer—increased overall and disease-free survival compared with chemoradiotherapy alone, according to the results of a study presented at the 2013 Gastrointestinal... Continue Reading

Surgeon Volume Influences Outcomes in Esophageal Cancer (February 6, 2013)

Patients who undergo surgery for esophageal cancer have a much higher chance of long-term survival if the surgeon has performed the operation many times before, according to the results of a study published in the Journal of Clinical Oncology. The esophagus... Continue Reading

Preoperative Chemoradiotherapy Improves Survival in Esophageal Cancer (September 10, 2012)

Preoperative chemoradiotherapy doubled median overall survival among patients with esophageal or esophagogastric junction cancer compared to surgery alone, according to the results of a phase 3 study published in the New England Journal of Medicine. The... Continue Reading

More Stages I-III Esophageal Cancer

Stages I-III Liver Cancer

Antiviral Therapy May Reduce the Risk of Tumor Recurrence in HBV-Related Liver Cancer (November 26, 2012)

Patients with hepatitis B-related liver cancer who receive antiviral drugs after curative surgery have a lower risk of recurrence compared to those who do not receive antiviral therapy, according to the results of a study published in the Journal of the... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (June 23, 2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (May 17, 2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (July 10, 2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading

Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer (March 8, 2009)

Differences in IMRT Radiation Doses May Complicate Study Results in Liver Cancer Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies... Continue Reading

More Stages I-III Liver Cancer

Stages I-III Pancreatic Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led... Continue Reading

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable (June 24, 2015)

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more... Continue Reading

Ruxolitinib Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation (June 2, 2014)

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with ruxolitinib plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer... Continue Reading

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients (May 23, 2014)

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses... Continue Reading

More Stages I-III Pancreatic Cancer

Stages I-III Rectal Cancer

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers (July 28, 2016)

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These... Continue Reading

Vectibix® Improves Survival in Colorectal Cancer, Demonstrates Importance of Tissue Testing (January 28, 2016)

The addition of Vectibix® (panitumumab) to best supportive care improves survival over best standard care alone among colorectal cancer patients who have stopped responding to chemotherapy. However, the benefit is only seen with patients who have no... Continue Reading

FOLFOX Improves Disease-Free Survival in Stage II and III Rectal Cancer Patients (June 11, 2014)

Researchers at the University of Ulsan College of Medicine in South Korea reported that treatment with the FOLFOX chemotherapy regimen in rectal cancer patients improved 3-year disease-free survival over a standard chemotherapy of 5-FU/leucovorin. The... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (November 6, 2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

Adjuvant Therapy May Offer Survival Benefit in Older Patients with Colorectal Cancer (September 11, 2012)

Adjuvant chemotherapy appears to offer a survival benefit to patients aged 75 years or older who have surgically resected colorectal cancer, according to the results of a study published in the Journal of Clinical Oncology. Colorectal cancer is the second... Continue Reading

More Stages I-III Rectal Cancer

Stages I-III Uterine Cancer

New Guidelines on Radiation Therapy After Surgery for Endometrial Cancer (July 9, 2015)

The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Society for Radiation Oncology (ASTRO) clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement... Continue Reading

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

Study Supports Laparoscopy for Uterine Cancer (March 5, 2012)

Compared with traditional open surgery (laparotomy), laparoscopic surgery for uterine cancer results in quicker recovery, slightly higher recurrence rates, and similar overall survival. These results were published in the Journal of Clinical Oncology. Each... Continue Reading

Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (August 9, 2010)

A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases. These findings were recently... Continue Reading

Laparoscopic Hysterectomy for Endometrial Cancer Associated with Better Quality of Life (August 3, 2010)

Laparoscopic hysterectomy for endometrial cancer that is confined to the uterus is associated with less pain, shorter hospital stays, faster recovery, and better quality of life when compared with total abdominal hysterectomy, according to the results... Continue Reading

More Stages I-III Uterine Cancer

Stages I-IIIA Lung Cancer - Non-Small Cell

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (October 19, 2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into... Continue Reading

Non-Small Cell Lung Cancer: The ALCHEMIST Lung Cancer Trials (January 14, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages II-III Bladder Cancer

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer (March 30, 2015)

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium... Continue Reading

Studies Evaluate Robot Assisted Cystectomy Treatment of Bladder Cancer (July 29, 2014)

The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder has a muscular wall that allows it to get larger and smaller as urine is stored or emptied. Bladder cancer is diagnosed in roughly 50,000 men and... Continue Reading

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer (June 23, 2014)

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting... Continue Reading

Immediate Cisplatin-Based Chemotherapy Extends Progression-Free Survival in Invasive Bladder Cancer (June 17, 2014)

A report at the 2014 American Society of Clinical Oncologists meeting indicates that immediate use of cisplatin-based chemotherapy offers significant improvement in progression-free survival over deferred treatment in invasive bladder cancer patients.... Continue Reading

Robotic Bladder Cancer Surgery Safe and Effective (January 24, 2013)

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder... Continue Reading

More Stages II-III Bladder Cancer

Stages II-III Breast Cancer

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

More Stages II-III Breast Cancer

Stages II-III Multiple Myeloma

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma among patients who do not intend to immediately... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma (December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly diagnosed multiple myeloma, according to the results... Continue Reading

Revlimid, Velcade, and Dexamethasone Followed by Revlimid Maintenance Appears Promising (July 22, 2014)

Researchers from France recently published the preliminary results of a clinical trial evaluating chemotherapy induction and consolidation treatment with Revlimid (lenalidomide), Velcade (bortezomib), and dexamethasone (RVD) followed by Revlimid maintenance... Continue Reading

More Stages II-III Multiple Myeloma

Stages II-IVA Cervical Cancer

Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (August 9, 2010)

A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases. These findings were recently... Continue Reading

Gemzar® Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer (June 8, 2009)

Gemzar® Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer The combination of Gemzar® (gemcitabine), Platinol® (cisplatin), and concurrent radiation significantly improves survival over single-agent Platinol and radiation... Continue Reading

January Is National Cervical Cancer Awareness Month (March 8, 2009)

January Is National Cervical Cancer Awareness Month As the month of January brings cervical cancer into focus, it’s a great time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment... Continue Reading

Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer (March 8, 2009)

Robotically-assisted Hysterectomy Appears Effective for Cervical Cancer Robotically-assisted hysterectomy (RAH) in patients with early-stage cervical cancer is at least as effective as traditional open radical hysterectomy (ORH) and produces fewer complications,... Continue Reading

Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers (March 8, 2009)

Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison... Continue Reading

More Stages II-IVA Cervical Cancer

Stages III-IV Gastric Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (June 28, 2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer (June 6, 2016)

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced... Continue Reading

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy (January 4, 2016)

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing... Continue Reading

Lynparza Improves Overall Survival in High-Risk Gastric Cancer (September 9, 2015)

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers... Continue Reading

More Stages III-IV Gastric Cancer

Stages IIIB-IV Lung Cancer - Non-Small Cell

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell

Stem Cell Transplant

Genetic profiling can guide stem cell transplantation for patients with myelodysplastic syndrome (February 21, 2017)

A single blood test and basic information about a patient’s medical status can indicate which patients with myelodysplastic syndrome (MDS) are likely to benefit from a stem cell transplant, and the intensity of pre-transplant chemotherapy and/or radiation... Continue Reading

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma (October 12, 2016)

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT) (December 14, 2015)

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to... Continue Reading

More Stem Cell Transplant

Supportive

Sorry, there are no articles available for this cancer stage.

More Supportive

Supportive Care

Yoga Improves Sleep Quality in Cancer Survivors (September 11, 2013)

Cancer survivors who participated in a special yoga program reported better sleep quality and less reliance on sleep medication, according to the results of a study published in the Journal of Clinical Oncology. Sleep problems and fatigue are among the... Continue Reading

Antidepressant Cymbalta May Reduce Pain from Chemotherapy-Induced Peripheral Neuropathy (May 24, 2013)

The antidepressant Cymbalta® (duloxetine) appears to reduce the numbness and tingling associated with taxane or platinum-based chemotherapy, according to the results of a study published in the Journal of the American Medical Association. Peripheral... Continue Reading

Neulasta Significantly Reduces Febrile Neutropenia Among Colorectal Cancer Patients Receiving Chemotherapy Plus Avasatin (February 25, 2013)

Neulasta® (pegfilgrastim) significantly reduced the incidence of grade 3/4 febrile neutropenia among patients with locally advanced or metastatic colorectal cancer who received chemotherapy with FOLFOX or FOLFIRI followed by Avastin® (bevacizumab),... Continue Reading

Exercise Reduces Cancer-Related Fatigue (November 30, 2012)

Aerobic exercise can relieve the fatigue associated with cancer and its treatment, according to an updated systematic review published in The Cochrane Library. Fatigue is one of the most common side effects of cancer and its treatment. There are many... Continue Reading

Naproxen May Relieve Bone Pain Associated with Neulasta (August 2, 2012)

Twice-daily naproxen is effective in reducing the incidence and severity of bone pain associated with the use of Neulasta® (pegfilgrastim), according to the results of a study published in the Journal of Clinical Oncology. Neulasta is a blood cell growth... Continue Reading

More Supportive Care

Supportive Care Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading

Ask the Expert: Breast Cancer, Diet and Exercise (May 19, 2014)

CancerConnect recently partnered with Dana-Farber to provide you with the opportunity to engage with a breast cancer expert, Jennifer A. Ligibel, MD, of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. On May 7 and 8, 2014, Dr. Ligibel... Continue Reading

More Supportive Care Breast Cancer

T

Sorry, there are no articles available for this cancer stage.

More T

T-Cell Non-Hodgkin's Lymphoma

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma (December 13, 2017)

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma... Continue Reading

Opdivo® Highly Effective for Some Patients with Lymphomas (August 16, 2016)

The immunotherapeutic agent, Opdivo® (nivolumab), appears to provide long-lasting anti-cancer activity among some patients who have received extensive prior therapy for both B- and T-cell lymphomas. These results were recently published in the Journal... Continue Reading

CAR Therapy Effective in Advanced Lymphoma (June 20, 2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types... Continue Reading

FDA Grants Fast Track Designation to SGX301 for First-Line Treatment of Cutaneous T-Cell Lymphoma (January 19, 2015)

The U. S. Food and Drug Administration has granted Fast Track designation the synthetic hypericin (SGX301) development program for the first-line treatment of cutaneous T-cell lymphoma. Fast Track designation from the FDA is reserved for drugs that demonstrate... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (December 17, 2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

More T-Cell Non-Hodgkin's Lymphoma

Testicular Cancer

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Testicular Cancer Rates on the Rise (June 24, 2013)

The incidence of testicular cancer continued to rise in the United States over the past decade, most notably among Hispanic men, according to the results of a study presented at the annual meeting of the American Urological Association in San Diego, California.... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Marijuana May Increase Risk of Testicular Cancer (September 21, 2012)

Recreational marijuana use may increase the risk of developing subtypes of testicular cancer that have a worse prognosis, according to the results of a study published early online in the journal Cancer. Testicular cancer is the most common cancer diagnosed... Continue Reading

More Testicular Cancer

Throat Cancer

Head and Neck Cancer-What You Need to Know (August 14, 2017)

Head and neck cancer includes a number of different malignant cancers that develop in or around the throat, larynx (voice box), nose, sinuses and mouth. Globally, head and neck cancer is the seventh most common type of cancer with an estimated 400,000-600,000... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

More Throat Cancer

Thyroid Cancer

Lower Thyroid Stimulating Hormone Levels Elevate Risk of Thyroid Cancer (September 20, 2017)

There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research... Continue Reading

Pass it On: It’s National Thyroid Awareness Month (September 8, 2017)

The thyroid gland is a butterfly-shaped organ that is below the Adam’s apple in the front part of the neck. It produces, stores, and releases hormones that regulate vital body functions. Thyroid cancer happens when cells in the thyroid grow out of control.... Continue Reading

Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid Cancer (June 6, 2017)

Two immunotherapy drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of melanoma also show promise for treating a rare but aggressive form of papillary thyroid cancer. Up to 44 percent of papillary thyroid cancer... Continue Reading

Thyroid Cancer Survivors May Have Increased Risk of Osteoporosis and Heart Conditions (March 3, 2017)

The results of a recent new study find that younger survivors of thyroid cancer are at increased risk for osteoporosis, high blood pressure and heart disease.  Thyroid cancer is the fifth most common cancer in women. The thyroid gland is a butterfly-shaped... Continue Reading

More Risk than Benefit with TSH Suppression in Thyroid Cancer without High Risk of Recurrence (May 21, 2015)

For patients undergoing treatment for thyroid cancer who aren’t at high risk of recurrence, therapy to suppress thyrotropin (TSH) may be ineffective as well as risky. These findings were published in the journal Thyroid. Differentiated thyroid cancer... Continue Reading

More Thyroid Cancer

Types of Cancer

Drug Payment Assistance Programs for Cancer (January 25, 2017)

Great advances have been made in the drug treatment of cancer leading to improved cure rates and longer survival. Managing a life threatening or chronic disease, cancer is difficult enough to begin with and can be made much more difficult if you are unable... Continue Reading

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers (December 5, 2016)

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be... Continue Reading

Syndros™ Approved for Treating Chemotherapy-Induced Nausea and Vomiting (July 12, 2016)

The orally administered liquid formulation, Syndros (dronabinol), has been approved by the United States Food and Drug Administration (FDA) for the treatment of chemotherapy-induced nausea and vomiting. Syndros is an oral formulation comparable to the... Continue Reading

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Fertility Rates Encouraging for Childhood Cancer Survivors (April 11, 2016)

Fertility rates, including pregnancy and livebirth rates, for both male and female childhood cancer survivors were recently analyzed in a large study, indicating promising data in this emotionally charged issue among young cancer survivors. The results... Continue Reading

More Types of Cancer

U

Sorry, there are no articles available for this cancer stage.

More U

Uncategorized

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia (June 23, 2016)

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior... Continue Reading

Lenvima® Approved for Kidney Cancer (May 24, 2016)

The United States Food and Drug Administration (FDA) has approved Lenvima® (lenvatinib) for the treatment of kidney cancer. The approval is for patients with advanced renal cell carcinoma who have received at least one prior therapy with an anti-angiogenic... Continue Reading

Mediterranean Diet May Lower Breast Cancer Risk (August 16, 2010)

Postmenopausal women who consume a traditional Mediterranean diet may have a lower risk for breast cancer, according to a study published in the American Journal of Clinical Nutrition. A traditional Mediterranean diet—one that is rich in fish, olive... Continue Reading

More Uncategorized

Uterine Cancer

New Guidelines on Radiation Therapy After Surgery for Endometrial Cancer (July 9, 2015)

The American Society of Clinical Oncology (ASCO) today issued an endorsement of the American Society for Radiation Oncology (ASTRO) clinical practice guideline on postoperative radiation therapy for women with endometrial (uterine) cancer. The endorsement... Continue Reading

Weighing the Risks (August 12, 2014)

Exploring the Link Between Obesity and Cancer By Kari Bohlke, ScD “For the great majority of Americans who do not use tobacco, weight control, dietary choices, and levels of physical activity are the most important modifiable determinants of cancer... Continue Reading

Radiation for Uterine Cancer May Increase Risk of Bladder Cancer (January 20, 2014)

Radiation therapy used to treat uterine cancer may increase the risk of bladder cancer later in life, according to the results of a study published in BJU International. Uterine (endometrial) cancer is one of the most common gynecologic cancers in women,... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

More Uterine Cancer

V

Sorry, there are no articles available for this cancer stage.

More V

Vaginal Cancer

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Vaginal Cancer

Video

Sorry, there are no articles available for this cancer stage.

More Video

W

Sorry, there are no articles available for this cancer stage.

More W

X

Sorry, there are no articles available for this cancer stage.

More X

Y

Sorry, there are no articles available for this cancer stage.

More Y

Z

Sorry, there are no articles available for this cancer stage.

More Z